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SUMMARY 
The use of assisted reproductive technologies has increased over the past decades. To date, 8 million 
children have been born worldwide following assisted reproductive technologies. In Switzerland, this 
refers to around 2-2.5% of newborn’s every year, this were 2’188 children in 2017.  
The introduction of this thesis gives an overview of the reasons for increasing global infertility, and of 
the use of medically assisted reproduction. It also presents the treatment options available today, 
and the risks associated with them for mothers and offspring. It goes on to describe the methods and 
data used in the research projects conducted for this thesis.  
In the following section, the four publications included in this thesis are presented. The first article on 
children within the Bern IVF Cohort compares the birthweights and birthweight percentiles of 
children born after natural cycle in vitro fertilisation, to those born after conventional in vitro 
fertilisation. This shows that the increased risk of small-for-gestational age infants being born may be 
associated with hyperstimulation of oocyte growth in conventional in vitro fertilisation, especially 
when high estradiol levels are reached on the day of ovulation induction.  
The second article uses follow-up data on breastfeeding collected within the Bern IVF Cohort. 
Breastfeeding prevalence and duration is compared to data from the Swiss Infant Feeding Study, 
which served as a control population. The findings demonstrate that women after fertility treatment 
breastfeed their children as much and for as long as mothers in the control population. This suggests 
that fertility treatment does not affect the potential and ability to breastfeed in Switzerland. 
The third article relates to the endometrium in natural cycle in vitro fertilisation, where the 
endometrium is not affected by hormonal stimulation. Data on endometrial thickness was collected 
from women during their first treatment cycle and the outcome measured, was successful 
pregnancy. It was shown that both very thin but also thick endometrium is associated with adverse 
pregnancy outcomes in natural cycle in vitro fertilisation.  
The fourth article analyses data from a historical cohort of women under treatment due to repeated 
implantation failure and recurrent pregnancy loss from 2014-2018. The two conditions seem to be 
associated with chronic endometritis, and their discussion is controversial: so far, no agreement on a 
standardised diagnosis or treatment has been reached. The aim was to assess the effect of 
endometrial diagnostic biopsy on subsequent treatment in cases of chronic endometritis, which was 
introduced in 2016, compared to hysteroscopic assessment alone. This demonstrated that diagnostic 
endometrial biopsy and subsequent treatment of chronic endometritis shortens time-to-pregnancy 




aOR Adjusted odds ratio 
AMH Anti-Müllerian hormone 
APS Antiphospholipid syndrome 
ART Assisted reproductive technology 
BMI Body mass index 
CC Clomiphene citrate 
CE Chronic endometritis 
CI Confidence interval 
cIVF Conventional gonadotropin stimulated in vitro fertilisation 
DNA Deoxyribonucleic acid 
DOHaD Developmental origins of health and disease 
EC Ethic commission 
ESHRE European Society of Human Reproduction and Embryology 
ET Embryo transfer 
E2 Estradiol 
FET Frozen embryo transfer 
FIVNAT-CH National registry on data from all ART treatment cycles in Switzerland 
FOPH Federal Office of Public Health (Bundesamt für Gesundheit) 
FSH Follicle stimulating hormone 
FSO Federal Statistical Office (Bundesamt für Statistik) 
GnRH Gonadotropin-releasing hormone 
hCG human chorionic gonadotropin 
HIV Human immunodeficiency virus 
HMG Human menopausal gonadotropins (includes FSH and LH) 
HR Hazard ratio 
ICMART International Committee for Monitoring Assisted Reproductive Technologies 
ICSI Intracytoplasmic sperm injection 
ISMAAR International Society for Mild Approaches in Assisted Reproduction 
IU International unit 
IUI Intrauterine insemination 
IVF In vitro fertilization
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The World Health Organization (WHO) and the International Committee for Monitoring Assisted 
Reproductive Technology (ICMART) define infertility as “a disease of the reproductive system defined 
by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual 
intercourse, or due to impairment of a woman’s capacity to reproduce”.1,2  
Some couples remaining childless is quite normal, as is couples having abundant offspring. Couples 
affected by infertility can seek medical help, at least in most countries of the developed world. 
However, infertility remains an ongoing problem worldwide, impacting gender equity and health 
equality. Unfortunately, the highest rates of infertility are often in countries with the most limited 
access to assisted reproductive technologies (ART).3 
It is important to respect infertility or subfertility as a disease, because affected couples often feel 
that their bodies are not working properly and healthily. They are not achieving what normal healthy 
couples can naturally achieve – namely, a pregnancy and a live birth of a child.4 According to the 
latest definition by the WHO, infertility is a disease, which constitutes a disability and an impairment. 
Sometimes infertility is the result of a disorder, which itself needs treatment and therefore should be 
diagnosed.4  
1.1.Infertility – epidemiology, aetiology and consequences 
Infertility is a highly prevalent condition and affects 8-12% of couples of reproductive age.5 
Worldwide, an estimated 97 – 186 million people are suffering from some form of infertility, 
infecundity or childlessness, mainly in developing countries.3,6,7 The inability to conceive following a 
prior pregnancy – secondary infertility – is the most common form of infertility worldwide. 25-30% of 
women of sub-Saharan African countries suffer from secondary infertility.6 A high prevalence of 
sexually transmitted infections may lead to female and male infertility. Additionally, poor maternity 
care, leading to post-abortive and postpartum infections, causes secondary infertility in females, 
especially in African countries.3,8 Despite the fact that in half of the infertile couples male factors 
contribute, it is often seen as a female failure, and the social burden falls on the woman, possibly 
leading to stigmatisation.8 The treatment and diagnosis of infertility is not only important for gender 
equity, but also in identifying possibly severe underlying health conditions generally reducing health-
related quality of life.4,8  
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Major factors affecting the likelihood of spontaneous conception are:  
- Time of unwanted non-conception (the longer a couple tries, the lower the chances become) 
- Age of the woman 
- Disease-related infertility 
Time of unwanted non-conception 
The time of unwanted non-conception is an important determinant of the severity of subfertility. 
Usually, 80% of pregnancies occur within six months of regular unprotected intercourse. After six 
more months, half of the remaining 20% of couples achieve a pregnancy. After 12 months of trying, 
the remaining 10% can be diagnosed with subfertility. However, even among this group, nearly 55% 
will achieve a spontaneous pregnancy within the next 36 months. 5% will remain infertile, with an 
extremely low chance of becoming pregnant.9 
Female age-related fertility decline & social trends  
In the 1960’s, the first hormonal contraceptive method, the anti-baby pill, came on the market. It 
allowed women to control their fertility and to become more sexually independent. Today, 73% of 
women aged 15-49 in Switzerland use some form of contraceptive method.10 At the same time, 
expectations for parenthood increased. Women aimed for better and longer educations, and focused 
on their professional careers. As a consequence of these societal changes, couples delayed starting 
their families, and the mean childbearing age in many countries increased.11,12 In Switzerland, the 
mean age of mothers at birth was 27.9 in the 1980s, 29.8 in 2000 and reached 32.2 in 2019.13 The 
total current fertility rate is below the replacement level of 2.1 in all European countries (average EU: 
1.6, World: 2.43).10 Delaying childbearing until less fertile ages is increasing involuntary childlessness, 
and is an important contributor to the decrease in births and fertility rates.14 Women are most fertile 
between the ages of 20-29. From 32 onwards, female fertility decreases gradually, and from 37 on, 
the decrease becomes more rapid. Women over 35 years do not only have more difficulties in 
becoming pregnant, but are also at a higher risk of loss of pregnancy.15 This is due to the continuous 
decrease of the ovarian reserve in both ovaries, and the hormonal change induced by the 
perimenopause. Additionally, deterioration of oocyte quality increases the risk of genetic aberrations 
and spontaneous abortions.16 Some women are at risk of entering menopause much earlier due to 
premature ovarian failure.17 With increasing age, the risk of health problems causing infertility, and 
the consequences of an unhealthy lifestyle become more important. Sadly, many men and women of 
younger ages are not aware of age-related declining fertility, and many believe ART can mitigate this 
problem.18 However, the response to ovarian stimulation in ART is lower if the ovarian reserve is 
reduced. This reduces levels of treatment success in older women. Either having already had a live 
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birth, or having donated eggs, increases the chance of a live birth through ART for women above the 
age of 40 years, but after 45 the chances are close to zero.19  
Disease related infertilities 
Many diseases, dysfunctions or malformations are associated with lower fertility or subfertility. 
Pathologies affecting the sexual functioning of the body or sexual organs, as well as systemic 
diseases, may influence fertility. It may affect both genders or be specific to one gender only.  
1.1.1. Female infertility 
Ovulatory dysfunction 
Ovulatory dysfunction means the non- or malfunction of the ovaries, and is usually characterized by 
fewer menstruations (oligomenorrhea) or no menstruation at all (amenorrhea). It is mostly caused by 
endocrine disorders, meaning the hormones regulating the female cycle are not produced in the 
necessary amount, or do not function normally. The most common endocrine disorder in women of 
reproductive age is polycystic ovary syndrome (PCOS), with a prevalence of 5-15%. The follicles fail to 
release the oocyte, which leads to numerous small persisting follicles in the ovaries which can be 
detected by ultrasound.20,21 In rare cases, ovulatory dysfunction is caused by genetic conditions such 
as Turner syndrome.22 
Tubal factor 
The fallopian tubes collect the oocyte after ovulation and transport it towards the cavum. Transport 
relies on effective ciliary activity, which can be impaired by inflammations or pathogens. The most 
common infectious diseases causing tubal problems are Chlamydia trachomatis or Neisseria 
gonorrhoea. Systematic diseases, such as primary ciliary dyskinesia or cystic fibrosis, can also impair 
ciliary structure and function. Further reasons may be tubal endometriosis, peritubal adhesions or 
salpingitis isthimica nodosa.5,23  
Uterine factor 
The uterine physiology and anatomy is important in the successful implantation of a fertilized egg. 
Uterine myomas are the most common benign tumours of the female reproductive system, and are 
present in 5-10% of infertile women, but are only the sole cause of infertility in 2-3% of infertile 
women. Their localisation may interfere with the implantation of the embryo.24 Other uterine 
abnormalities such as fibroid, polyps, or adenomyosis can also reduce the chance of achieving a 
pregnancy.25 Congenital uterine malformations such as uterus septus or subseptus, or more complex 
malformations such as uterus unicornus, bicornus or didelphys, may in rare instances lead to 
infertility or recurrent pregnancy loss.26 Surgical treatment is sometimes needed. 
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Endometriosis 
Endometriosis is characterised by the presence of endometrial mucosa (the lining of the uterus) in 
other locations within the female pelvic area. It is a pathological and chronic inflammatory process. 
Some women have cyclical abdominal pain and/or pelvic pain during or after sexual intercourse. The 
severity and localisation of endometriosis can vary highly. The association of endometriosis with 
infertility ranges from anatomical distortions due to adhesions and fibrosis, to endocrine 
abnormalities and immunological disturbances.27 Endometriosis decreases the embryonic 
implantation potential, which reduces ART success. It also leads to a higher risk of miscarriages 
independent of the origin of the pregnancy.28 Endometriosis often remains undiagnosed. Its 
prevalence in women of reproductive age is unclear, and estimates range from 0.8% to 10%. In 
subfertile women it ranges from 20-50%.29,30  
1.1.2. Male factor infertility 
Male infertility contributes to 40-50% of cases where a couple is infertile, and in 20-30% it is the sole 
cause. Male infertility is mostly due to testicular deficiency or post-testicular impairment. Both can 
be congenital, acquired or idiopathic. Congenital problems may be the malformation or lack of 
testicles, the absence of vas deferens in men with cystic fibrosis or genetic abnormalities. Genetic 
abnormalities are Klinefelter (47 XXY) syndrome and Y chromosome microdeletions, causing issues 
from a light disturbance of spermatogenesis up to a complete azoospermia.5,25 Trauma, testicular 
torsion or inflammation of the testes can lead to testicular failure, as can medication or varicocele 
(varicose veins in the scrotum). Varicocele are present in 14.8 - 25.4% of men with abnormal 
semen.31 Ejaculatory dysfunction (retrograde ejaculation) or obstruction in the epididymis, vas 
deferens or ejaculatory duct can be the result of infections, vasectomy or hernia repair. About 6% of 
men produce antibodies against their own sperm.5,31 
Another important issue in male fertility is the worldwide decrease in sperm quality seen over the 
last decades.32 In 2010 the WHO lowered their reference limits for human semen characteristics 
based on men whose female partner got pregnant within 12 months (volume: 1.5ml; total sperm 
count: 39 million; sperm concentration: 15 million/ml; vitality: 58%, progressive mobility: 32%; 
motility: 40%; and 4% morphologically normal forms). In a study on the semen quality of young men 
recruited for the Swiss army, only 38% reached the sperm concentration, motility and morphology 
values of the WHO semen reference criteria. The median sperm concentration was among the lowest 
in Europe.33 The reasons for this trend are manifold, but environmental and lifestyle factors seem to 
play important roles. The consumption of caffeine, nicotine, alcohol and fatty acids, and a diet rich in 
full fat diary, meat and sugar, as well as obesity, potentially reduce fertility in men.32,34 Chemicals 
with a hormonal influence on the body (endocrine disrupting compounds) can interfere with female 
18
  Introduction 
 
and male fertility. Other pollutants such as organohalogens, air pollutants or heavy metals such as 
mercury could influence semen quality, as could pesticides and herbicides used in agriculture.35,36 
1.1.3. Idiopathic infertility 
In around 20-30% of infertile couples, infertility remains unexplained. It may be due to subtle, 
undetectable defects in the reproductive process, or just due to incidentally reduced fecundity. Many 
chronic or systematic diseases may influence fecundity. This is true of unstable diabetes, 
uncontrolled celiac disease and active autoimmune conditions, which may also be subclinical.37,38 
Psychological stress, lifestyle factors, use of caffeine or nicotine, too much or too little body weight 
and extensive sport training may be associated with lower fertility in men and women.36,39,40 
Repeated implantation failure and recurrent pregnancy loss 
Among the main challenges in fertility treatment remain repeated implantation failure (RIF) and 
recurrent pregnancy loss (RPL) as stated by the European Society of Human Reproduction and 
Embryology (ESHRE). RIF means the failure to reach a stage of clinical pregnancy after several ART 
cycles with subsequent embryo transfer, but no distinct definition exists.41 RPL is defined as three or 
more consecutive miscarriages by the WHO and 1-5% of women are affected.42–44 Risk factors 
associated with RIF and RPL are parental age, obesity, environmental exposure (including smoking 
and alcohol), genetic factors, uterine malformations and thyroid autoimmunity. Antiphospholipid 
syndrome is a distinct risk factor for RPL.44 Additional factors related to IVF therapy might play a role 
in RIF: gamete/embryo factors such as oocyte quality, sperm quality (e.g. deoxyribonucleic acid 
(DNA)-fragmentation), ovulation induction protocol, hydrosalpinges and assumed immunological and 
pathophysiological factors. Other physiological and immunological factors have recently been 
discussed in relationship to RIF and RPL (e.g. natural killer cells, T-helper 1/T-helper 2 ratio and 
tumour necrosis factor 
implantation window), but more research is needed to provide evidence of any association.45,46 
Imbalances of the uterine immunological cell pattern can lead to persistent inflammatory processes, 
and to chronic endometritis (CE). CE often remains undiagnosed, as it can be subtle and 
asymptomatic, or present with untypical symptoms such as pelvic pain, vaginal discharge, abnormal 
bleeding, dyspareunia and leucorrhoea.47,48 ART cannot successfully bypass CE, as the problem lies in 
the implantation of the embryo. There is little agreement on standardized diagnosis and treatments 
for CE.49 The formation of the first connection to the uterine endometrium, and the maintenance and 
support of this connection to establish a secure pregnancy, is a very complex process. 
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The following section clarifies and defines terms often used in medically assisted reproduction (MAR) 
and assisted reproductive technologies (ART).  
Medically assisted reproduction includes “various interventions, procedures, surgeries and 
technologies to treat different forms of fertility impairment and infertility. These are ovulation 
induction, ovarian stimulation, ovulation triggering, all ART procedures, uterine transplantation and 
intra-uterine, intracervical and intravaginal insemination with semen of husband/partner or donor”.1  
Assisted reproductive technologies “includes all interventions with the in vitro handling of both 
human oocytes and sperm or embryos for the purpose of reproduction”.1 This includes in vitro 
fertilisation (IVF), embryo transfer (ET), intracytoplasmic sperm injection (ICSI) and many other 
treatments which are not relevant for this thesis. Importantly, ART does not include assisted 
intrauterine insemination (IUI).1 In this thesis, the term ART is used when referring to children born 
after IVF or ICSI.  
The term subfertility is interchangeable with infertility. Infertility and subfertility are defined by a 
specified time period; this is one year of unwanted non-conception, per the WHO definition. Sterility 
is a permanent state of infertility.1 
A further distinction can be made between primary and secondary infertility. A woman with primary 
infertility has never been diagnosed with a clinical pregnancy. Secondary infertility means that a 
woman has previously been diagnosed with a clinical pregnancy, but is not able to establish a further 
clinical pregnancy.1 
1.2.2. Development and global perspective 
In England in 1978, the first baby was born through IVF. This success was among the major medical 
breakthroughs of the 20th century. IVF was in this case developed to overcome the mother’s blocked 
tubes.50,51 Since Steptoe, Edwards and Purdy succeeded with IVF, the use of ART has increased 
worldwide.51 Approximately 8 million children have been born following ART since 1978, mainly in 
high-income countries.3 In developing countries, access to adequate fertility treatment is still difficult 
and unaffordable for many, although access is improving every year.3 Even in developed countries, 
health insurance does not always cover ART, compromising reproductive autonomy.52,53 Many 
infertile couples benefit from improvements in MAR. In only 40 years, many technologies have been 
developed to address different causes of infertility.50  
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1.2.3. Fertility treatment 
Fertility treatment usually starts with the investigation of the couple for the cause of subfertility. 
Firstly, a comprehensive assessment of the medical, gynaecological and urological histories, the 
function of sexual organs, clinical investigation and specific diagnostic tests are conducted. These 
tests usually include a transvaginal ultrasound examination including the antral follicle count to 
assess ovarian reserve. At the beginning of the cycle a measurement of serum hormones (follicle 
stimulating hormone (FSH), luteinising hormone (LH), estradiol (E2), thyroid stimulating hormone 
(TSH), prolactin and total testosterone) are performed. Anti-Müllerian hormone (AMH) is measured 
for additional information on the ovarian reserve. Preovulatory a hysterosalpingography is 
performed to assess uterine cavity and the patency of the tubes. Male fertility is assessed by the 
analysis of ejaculate including concentration, motility, and the morphology of the sperm.22,25  
Today, many causes of infertility are treatable with different techniques developed in MAR. IUI and 
monofollicular ovarian stimulation may be sufficient for couples with less severe fertility problems, 
where a spontaneous conception is possible. Both the stimulation and the inhibition of ovulation are 
important factors in synchronising ovulation within the cycle. If supported spontaneous conception is 
not successful or possible, the fertilisation can be done in culture in a laboratory. Sperm is collected 
to inseminate retrieved oocytes outside the human body.  
Hormonal ovarian stimulation supports the growth of more than one oocyte and impedes the natural 
selection of just one oocyte. Ejaculate is provided by the man himself, and then worked-up in the 
laboratory to select high quality sperm. The oocyte is fertilized in vitro either by adding an amount of 
sperm to the oocyte (IVF), or by the injection of just one selected sperm directly into it (ICSI). ICSI was 
originally developed to overcome severe male infertility, more than 25 years ago. In 2015, ICSI was 
used in 71.2% of treatments in Europe, avoiding natural sperm selection.54  
The fertilized oocytes are cultured for several days before they are transferred to the uterus of the 
mother. This is a fresh embryo transfer. They are either transferred at the cleavage stage (day 2 or 3) 
or at the blastocyst stage (day 5) of their development. The extension of culture duration allows a 
better assessment of embryo quality, as their morphological structure, their kinetics and their longer 
survival are good indicators of viability. Freezing techniques have been developed to store 
supernumerous embryos. Current vitrification techniques allow storage and the thawing of embryos 
to be transferred in later cycles. This is called a frozen embryo transfer (FET). The advantage of a FET 
is that the uterus, especially the endometrium, can be specifically prepared. The disadvantage is that 
the embryo can get damaged by the vitrification technique. Today, it is possible to diagnose embryos 
for genetic defects before transfer to the uterus. This is called preimplantation genetic testing. If a 
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couple is a known carrier of a hereditary disease, a few cells of the embryo can be genetically 
analysed for this mutation. This allows the selection of a healthy embryo for transfer. It is even 
possible to screen an embryo’s potential to develop unknown chromosomal or structural 
aberrations. 
Some versions of MAR are not legal in Switzerland, such as the donation of oocytes or surrogacy 
motherhood. Sperm donation, on the other hand, is allowed. All these technologies and many more 
developed in the last 40 years.55 Reproductive medicine is a relatively young medical field. 
Cumulative pregnancy rates in ART can under optimal conditions reach natural fertility rates.56 
However, even with ART support, a proportion of couples will remain childless. Unsuccessful fertility 
treatment can lead to psychological distress, or to problems in the couple’s relationship.57,58 
Reproductive medicine is also an area of conflict in many societies. It is caught between ethical, 
religious and legal factors which shape the options and attitudes of the couples affected, and the way 
they access and experience support.57 Health insurance coverage differs between countries.52 
Different legal restrictions, costs and access to treatment options increase cross-border fertility 
tourism between countries and continents.59 
1.3.Treatment schemes used at the University Women’s Hospital in Bern 
At the University Women's Hospital in Bern, individual and patient-oriented IVF therapy is important. 
Therefore, natural cycle IVF (NC-IVF) is offered as an alternative alongside conventional gonadotropin 
stimulated IVF therapies (cIVF). In Switzerland, this is only the case at Bern, Baden, St. Gallen and 
Lausanne, but Bern has the longest experience with this treatment. Centres are organized within the 
IVF-Naturelle (www.ivf-naturelle.ch) network. This chapter gives an overview of the IVF treatments 
conducted at the Bern IVF center. The focus is on treatments with IVF/ICSI fertilization followed by a 
fresh embryo transfer.  
Natural cycle IVF (Schema A) 
In natural cycle IVF, gonadotropins are avoided for the stimulation of oocyte growth. The focus is on 
natural follicle recruitment and selection. The women undergoing NC-IVF have a regular menstrual 
cycle (26-32 days), and at least one ovary accessible transvaginally for the oocyte pick-up (OPU) 
needle. The treating physicians monitor the cycle by ultrasound, and measure levels of E2 and LH 
once before the ovulation is expected. When the follicle reaches a diameter of at least 16 mm and 
the estimated E2 level reaches > 700 pmol/L, a single injection of 5’000 international units (IU) of 
human chorionic gonadotropin (hCG) is given, to trigger the ovulation. Within 36 hours, follicular 
aspiration is conducted using a 19G single lumen needle, without anaesthesia. Follicular flushing up 
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to five times increases the chance of collecting the oocyte.60 In case of the LH surge (>10 IU/L) on the 
day of trigger administration, 400 mg ibuprofen is given every 8 hours until the day of follicular 
aspiration.61,62 Non-steroidal anti-inflammatory drugs (NSAID) such as Ibuprofen or indomethacin can 
postpone the ovulation by several hours if started before or at the onset of the LH surge.63,64 If the LH 
surge is already high, the OPU is planned within 24 hours in order not to miss the oocyte. In NC-IVF 
there is always a risk that ovulation has already taken place, and the oocyte is lost. Besides NSAID, 
there is also the possibility of giving a single injection of a gonadotropin-releasing hormone (GnRH) 
antagonist if the LH surge has not yet started. This can be used to postpone follicular aspiration by 
one day for organisational reasons (e.g. not on a Sunday). 
NC-IVF using clomiphene citrate (Schema C) 
Low-dose clomiphene citrate can reduce the risk of premature ovulation by delaying the premature 
LH surge. The woman takes 25 mg every morning from cycle day 6 or 7, depending on the cycle 
length, until the day when ovulation is triggered by 5’000 IU of hCG. The subsequent procedure 
remains similar to the NC-IVF protocol described above.61,62 Clomiphene citrate can reduce 
premature ovulation by 21%, and increase subsequent ET rate by 14.6%.62 However, higher doses of 
clomiphene citrate should be avoided, as they can reduce endometrial thickness.25 
Minimal stimulation IVF (Schema E) 
If a woman under IVF treatment has a thin endometrium and is at high risk for preterm ovulation, a 
minimal hormonal stimulation can be used (mIVF). The woman injects Merional® 75 IE from cycle day 
3-5, until one day before the administration of HCG for ovulation trigger. Merional® is human 
menopausal gonadotropin, which is a mix of human FSH and LH. Menopausal gonadotropin is gained 
from the urine of postmenopausal women. When the diameter of the leading follicle is 18-20 mm, 
and E2 -800 pmol/l, 5’000 IU of hCG is injected and oocyte 
retrieval is conducted 36 hours later as described above. If many follicles have developed, OPU is 
conducted with anaesthesia. This stimulation scheme is similar to a cIVF protocol using antagonists, 
with much lower doses of gonadotropins.25,65 Low-dose gonadotropins are sometimes combined with 
clomiphene citrate if a better response to the stimulation is desired.25,66,67  
Conventional gonadotropin stimulated IVF 
The vast majority of ART treatments worldwide are performed with cIVF. For multifollicular 
stimulation, HMG was primarily used, and is still used, but because of HMG’s urinary origin, the use 
of recombinant FSH is more common nowadays.68  
Generally in cIVF, multifollicular growth is stimulated by FSH and a GnRH agonist or antagonist is 
added in combination to inhibit the gonadotropin production of the pituitary gland. This suppresses 
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LH release from the pituitary gland and prevents spontaneous ovulation. As LH surge therefore does 
not naturally occur, the ovulation has to be induced by hCG or GnRH agonists, artificially creating an 
LH surge. Without the LH surge, the first meiotic division and morphological changes of the oocytes 
would not occur.  
In Bern, different cIVF treatment protocols are used, with gonadotropin agonists or antagonists. In 
the short or long agonist protocol, the downregulation with Decapeptyl® (GnRH agonist) starts from 
day 1 of the menstrual cycle (short), or in the mid-luteal phase of the preceding cycle (long). The 
stimulation with 150-300 IU of gonadotropins (either HMG, e.g. Merional®, Menopur® or FSH, e.g. 
Gonal-F® or Pergoveris®) starts from cycle day 2-3.69,70 The physician individually decides the dose 
and the exact product based on the age, body mass index (BMI), AMH level, and antral follicle count 
and medical history of the woman.  
For the antagonist protocol, 150 – 300 IU HMG are administered for follicular stimulation once a day. 
From day 6 to 8 onwards, the GnRH antagonist (e.g. Cetrotide® or Orgalutran® 0.25 mg) is added to 
avoid preterm ovulation. In all cIVF protocols, cycles are monitored by ultrasound and serum E2 level 
is measured. Once the leading follicles reach a diameter of at least 18 mm, and the concentration of 
E2 corresponds to the number of follicles, ovulation is triggered by urinary hCG (e.g. 6500 IU 
Ovitrelle®). The transvaginal oocyte retrieval takes place 36 hours after hCG administration under 
conscious sedation.71,72 
Due to the downregulation of the pituitary gland and to the reach of supraphysiological E2 levels, the 
luteal phase after gonadotropin stimulation is insufficient. Progesterone is vaginally administrated to 
prepare the endometrium for implantation after embryo transfer up to 12 weeks of gestation.73 
Definition of different treatments 
NC-IVF is defined by the International Society for Mild Approaches in Assisted Reproduction 
(ISMAAR) as IVF without the use of any medication. However, it is also used as an umbrella term for 
all IVF treatments not using gonadotropins or other stimulating hormones for follicular growth. Von 
Wolff suggests naming these treatments “monofollicular IVF”, even if certain medications are used to 
support steps within the cycle to improve the outcome. He suggests further distinguishing between 
minimal stimulation IVF, and conventional IVF. In minimal stimulation IVF, a lower dose of 
stimulating hormones is used to stimulate the growth of some follicles. This could be named 
“oligofollicular IVF”. In conventional IVF, GnRH antagonists or agonists are used to suppress the LH 
surge and to stimulate the growth of many follicles, which should be named “polyfollicular IVF”.61  
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1.4.Perinatal health of children born after ART 
The first successes in ART soon met with religious and ethical concerns. In ART, the treatment not 
only affects the parental couple, but also the offspring. Concerns followed about complications in 
pregnancy and birth, and over the health of children conceived using ART.74 Perinatal outcomes for 
ART children have since been comprehensively studied. There are many risks, which are particularly 
associated with multiple births, but are also present in single births after ART.75 The first systematic 
reviews on singletons with data from the 80’s and 90’s showed a twofold higher risk of preterm birth 
(PTB), low birthweight (LBW) and small-for-gestational age (SGA), in comparison to spontaneously 
conceived singletons.75,76 Later systematic reviews and meta-analyses (after the year 2000) still found 
an odds ratio (OR) of 1.5 for preterm birth.77,78 Anja Pinborg et al. found increased risks of preterm 
birth in spontaneously conceived children when time-to-pregnancy was more than one year 
(adjusted OR 1.35).78 Furthermore, they found higher risks in ART singletons as compared to their 
spontaneously conceived siblings (aOR 1.27, 95% CI 1.08 – 1.49), suggesting that factors related to 
ART methods per se may still play a role.  
Epigenetic modifications control the activity of genes, but do not change the DNA structure. They are 
either associated with the health and fertility levels of the parents, or are a consequence of the early 
environment of the embryo. The first epigenetic programming occurs during gametogenesis in either 
parent. A second wave of epigenetic reprogramming happens at fertilization with the demethylation 
of the paternal and maternal genomes.78,79 Several studies show differences in DNA methylation 
levels in children born after ART.80–82 However, a recent study demonstrates that this epigenetic 
changes seem not to persist into adult life.83 
Researchers have identified various factors, which may increase the risk of ART causing epigenetic 
changes during conception, pregnancy and early life. These are:  
- Hormonal stimulation 
- Fertilisation 
- In vitro culture 
- Cryopreservation 
The following section offers some insight in the possible associations.  
Hormonal stimulation 
Hormonal stimulation may interfere with oocyte selection, follicular fluid and early pregnancy.84–86 
Epigenetic changes may occur during gametogenesis, and in genes critical to endometrial 
remodelling during early implantation.87  
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Different stimulation protocols used within ART have been comprehensively researched and 
discussed, with a focus on the type and total dose of hormones used.88,89 Research suggests that the 
birthweight and gestational age of newborns is lower after gonadotropin stimulation.90–93 This is 
especially true when women show a high response to the stimulation, which leads to 
supraphysiological estrogen levels around ovulation, and so to superovulation.94 Low birthweight and 
small-for-gestational-age, as well as the risk of preterm birth, seem to be associated with high 
estrogen levels and a high number of oocytes.95–97 However, the risk of low birth weight also seems 
to be influenced by parental characteristics and pregnancy conditions.98 
Fertilisation 
In IVF, several sperms compete for fertilisation. In ICSI an embryologists arbitrary selects a single 
sperm to inject it into the oocyte, which is quite invasive. However, compared to IVF, most large 
studies found similar or lower risks for PTB and LBW in singletons born after ICSI. A large cohort 
study found an association between ICSI and a higher risk of birth defects, but this was not confirmed 
by a meta-analysis.99,100 Male infertility is inherited from the father by male offspring born after 
ICSI.101,102 
In vitro culture 
Culture procedures in the laboratory seem to introduce epigenetic changes in the sensitive phase of 
foetal programming.103,104 It has been shown that two culture media, from different manufacturers, 
lead to differences in birthweight. Although the components in the culture media are known, the 
manufacturers do not disclose the exact concentrations.105–108  
Changes in Swiss law, and advances in culture techniques, have permitted embryo culture up to day 
five, until the embryo reaches the blastocyst stage. This enables the self-selection of viable embryos, 
and a better synchronisation with the maternal cycle. A Cochrane review showed increased live birth 
rates after fresh blastocyst transfer by OR 1.48 (95% confidence interval (CI) 1.20 – 1.82), as 
compared to cleavage stage transfer.109 Blastocyst transfer may also lead to higher birthweight.110 
However, blastocyst transfer was also associated with a higher risk of preterm and very preterm 
delivery, although the risk of intrauterine growth restriction was lower.111 
Cryopreservation 
To minimise the risks of hormonal stimulation to the onset of pregnancy, freeze-all strategies are 
becoming increasingly proposed. A single thawed embryo is transferred during a normal menstrual 
cycle, without gonadotropin stimulation of oocyte growth but only hormonal preparation of the 
endometrium. Babies born from the transfer of thawed embryos have a higher risk of increased 
birthweight and large baby syndrome.112–114 A meta-analysis concluded there was a lower risk of 
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preterm delivery, low birth weight and small-for-gestational age. However, a systematic review and 
meta-analysis found the risks of preeclampsia and of hypertensive disorders during pregnancy, were 
found to be higher.115 This result was confirmed by a large randomised controlled trial conducted in 
China, in which they also found a higher pregnancy rate after single frozen blastocyst transfer.  
Multiple pregnancies 
Multiple pregnancies are increased in ART due to the transfer of more than one embryo. Often 
multiple embryos are available after hormonal stimulation. Despite the fact that multiple 
pregnancies are associated with higher risks, the transfer of multiple embryos increases pregnancy 
and live birth rates.116 Many experts support the elective single embryo transfer (SET) strategy. 
Therefore, in some countries, laws or insurance policies encourage or require the use of SET.117 Even 
when a singleton is born after the transfer of more than one embryo, there are increased risks. If one 
embryo does not develop further, this is called a vanishing twin. The remaining singleton is 
physiologically still seen as a twin during the pregnancy. This can lead to intrauterine growth 
restrictions, with subsequent lower birth weight and a higher risk of being SGA.118,119  
Risks for the mother 
Hormonal stimulation likewise increases risks for the mother-to-be. The use of hormones is always 
associated with a higher risk for thrombosis in women. Furthermore, ovarian hyperstimulation 
syndrome (OHSS) is clearly associated with high-dose gonadotropin or clomiphene stimulation. The 
risks are generally not foreseeable, as they are dependent on the individual’s reaction on the 
stimulation. OHSS is mainly characterised by increased vascular permeability and ovarian 
enlargement. OHSS can range from mild to severe, and in rare cases is even fatal. Moderate to 
severe cases may occur in 3-10% of cases.120  
In extensive meta-analyses or cohort studies, the following risks have been found to significantly 
increase during pregnancy after ART: pregnancy-induced hypertension, gestational diabetes, 
placenta praevia, placental abruption, ante- or postpartum haemorrhage, and, in multiple 
pregnancies, the premature rupture of membranes. This puts the health of child and mother at risk 
of complications and preterm birth.121,122 ART children are more frequently delivered by caesarean 
section. It is not clear whether this is due to parental wishes, whether complications occur more 
frequently or simply whether obstetricians tend to be especially careful.77,112,122 However, an Italian 
study comparing the delivery of uncomplicated singleton term pregnancies still found higher odds of 
operative delivery for ART children (adjusted OR 1.40; 95% CI 1.01-1.95), and this is also true within 
the Bern IVF cohort.123 
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Research on NC-IVF 
NC-IVF allows research into the influence of gonadotropin stimulation, as outcomes can be compared 
to those of cIVF. As SET is standard, multiple pregnancies can easily be avoided in NC-IVF. Research at 
the University Women’s Hospital in Bern has proven NC-IVF to be less stressful for infertile 
patients.124 It is less expensive but more time consuming per achieved pregnancy when compared to 
cIVF.66,125 In NC-IVF, the quality of the embryo seems to be better, due to natural follicle selection 
and fewer alterations of the follicular fluid.126–128 Implantation and placentation seem to be improved 
due to increased endometrium receptivity.85,86,129,130 NC-IVF and minimal-stimulation IVF are 
valuable, cost-effective alternatives to cIVF, and it is important to investigate the possible reduction 
of further risks associated with ART by promoting NC-IVF.66,131 
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1.5.Long-term health of children born after ART 
In David Barker’s investigations into infant mortality and stroke, he found a relationship between 
conditions in early life and later health outcomes. At that time, low birthweight was the most 
frequent cause of infant mortality.132 He developed the theory of developmental origins of health 
and disease (DOHaD).133 In a Finnish cohort, in which fetal growth was measured, he identified fetal 
growth restriction, undernutrition and compensatory growth in childhood as the key risk factors 
associated with cardiovascular risk and type 2 diabetes. He postulated that the circumstances of 
conception, and conditions during pregnancy, may influence later health, even in adult life. Hunger 
and growth restriction in the womb may especially affect cardiometabolic outcomes.134 Some 
concerning results have recently been published regarding the cardiovascular health of children born 
after ART. A Spanish research group found cardiovascular remodelling even during pregnancy in 
foetuses conceived through ART, which persisted until age 3. 135,136 A cohort study conducted in 
Switzerland found increased intima-media thickness, increased flow-mediated dilation, higher pulse 
wave velocity and higher blood pressure in children at age seven to nine born after ART.137 These 
findings were later found to persist into adolescence (16-18 years).138 A study of an ART cohort at the 
Netherlands found elevated blood pressure at age four, although this was not found to persist at age 
nine.139–141 An Australian study of 193 ART and 86 non-ART adults did not find elevated vascular or 
cardiometabolic risks, when adjusted for important perinatal factors and quality of life.142 A recent 
systematic review and meta-analysis including 19 studies with 2’112 ART and 4’096 non-ART 
children, found small but significantly higher blood pressure levels in ART children. 143  
Singletons born after IVF perform well in neurological and mental development, and show normal 
intelligence, although Zhu et al. found a modest delay in psychomotor developments in a large 
Danish birth cohort.144,145 However, the duration of infertility seems to be associated with lower 
cognition and behavioural performance.146 The incidence of autism spectrum disorders seems to be 
inconclusive, but rather not to be elevated in singletons, but is in multiples following ART.147,148 Initial 
results in adolescents show no persistence of autism spectrum disorders.149 A tendency toward an 
increased risk for cerebral palsy has been observed, mainly associated with preterm birth or 
multiples.144,145 No difference has been identified regarding growth (weight & height) in ART children 
in comparison to spontaneously conceived children.150–152 
Cancer is very rare during childhood; it is therefore difficult to identify differences between ART and 
non-ART children. Two systematic reviews and meta-analyses summarized several large cohort- and 
linkage studies, and found a small but significantly increased risk for all types of childhood cancer in 
children born following ART.153,154 The more recent review from 2019 found that risks were mainly 
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increased for leukaemia and retinoblastoma.154 Two recent studies from the USA and Denmark, not 
yet included in the latest reviews, found a significant association between childhood cancer and 
frozen embryo transfer.155,156 
The question of whether children conceived through ART are at an increased risk of infections, 
especially severe infections requiring hospitalisation, has mainly been studied by looking at general 
health and morbidity or hospital admissions.157–163 A somewhat increased risk was mainly associated 
with multiple births and lower birthweight.160,163 For infectious and parasitic diseases, Kettner et al. 
found in their review eight studies presenting odds ratios (OR) between 0.37 – 5.7.164 For the burden 
of otitis media, acute tonsillitis, urinary infections or pneumonia, Kallen et al. found a higher odds 
(OR 1.08 – 1.33) among ART children, in a population based study,161 whereas Pinborg et al. did not 
find differences in a questionnaire-based study in which they compared ART twins to ART singletons 
and SC twins.160  
Only a few immune-mediated diseases have been studied in ART children. Of these, asthma is 
probably the most studied.165–170 Many of these studies show an association between ART and 
increased odds ratios from 1.9 to 6.0.157,159,161,167,168 Those studies which have information on parental 
subfertility (time to conception), all found a higher risk of asthma among the spontaneously 
conceived children of subfertile parents, as compared to the children of parents without fertility 
problems.168,169,171,172 Kuiper et al. found the higher use of asthma medication in ART children to be 
associated with hormonal-stimulated IVF, as compared to modified natural cycle IVF.173 Two studies 
on adolescents and young adults describe a higher prevalence of breathing problems and asthma in 
ART children; however, this difference was no longer observed in adolescence.142,166  
Another important disease to look at is type 1 diabetes. Only two studies have been published on the 
topic, both very recently.174,175 Norrman et al. found increased HR for diabetes type 1 in an 
unadjusted analysis, but no longer once adjusted. They also observed an association between type 1 
diabetes with FET.175 Kettner et al. found no association between type 1 diabetes and fertility 
treatment in a primary analysis, but found some increased risk associated with follicle-stimulating 
hormones in a secondary analysis.174 However, while these two studies remained somewhat 
inconclusive, there is evidence that glucose metabolism might be altered by ART.143,176 This may 
increase the risk of the development of type 2 diabetes later in life. The DOHaD theory also supports 
this hypothesis. As low birthweight is associated with impaired metabolic functions, a higher 




2. Methods and data 
In the following section, the study designs and data sets used in the different projects included in this 
thesis will be presented.  
2.1.The Bern IVF Cohort  
The main data source for this thesis is the Bern IVF Cohort. I coordinated the cohort’s establishment 
by helping secure ethical approval, setting up the RedCap database and recruiting the participants. 
One of the main aims of my thesis was the set-up of a control group of spontaneously conceived 
children. I performed the matching of cohort members with control group members, and 
coordinated the participant recruitment and data collection.  
The aim of the Bern IVF Cohort is to compare different fertility treatments, mainly NC-IVF and cIVF. 
NC-IVF avoids gonadotropins for stimulation of oocyt  IU of gonadotropins 
per day for the stimulation. The Bern IVF Cohort allows comparison of outcomes between the two 
treatments. This allows estimating influence of hormonal stimulation on pregnancy and health of 
children. In Bern, NC-IVF and cIVF are offered, and sufficient numbers of both treatments are 
conducted to allow comparison. The cohort is therefore unique, both in Switzerland and even at an 
international level. 
2.1.1. Bern IVF Cohort - description 
The Bern IVF cohort was established in 2016-2017, retrospectively including woman treated from 
2010 to 2015, and with the aim of including women treated in 2016 and 2017. The registration of 
women treated in 2017 is not yet complete. Data is collected on parental characteristics, medical and 
fertility history, ART treatment, pregnancy complications and outcome, the characteristics of births 
and perinatal health. Follow-up data on breastfeeding duration and child growth until age four is also 
collected. All participants are contacted for informed consent, and receive a newsletter every year. 
The newsletter contains information about current and planned projects, and helps in keeping 
addresses updated. The Bern IVF cohort has ethical approval, issued by the cantonal ethics 
committee of Bern (No. 2012-00235).  
Inclusion criteria: All couples (mothers and fathers) where the woman was 18-42 years at the time of 
treatment, and all children born after successful IVF treatment and fresh embryo transfer performed 
at the Bern University Hospital from 2010-2017.  
Exclusion criteria: Children born after FET, and women whose treatment cycles did not lead to a 
pregnancy. Pregnancy as defined as having had one positive pregnancy test for hCG.
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In 2017, the law governing reproductive medicine in Switzerland was changed, allowing for a longer 
duration of embryo culture. This change was adopted from October 2017 onwards at the Bern 
University Hospital. Women treated after this change are not recruited into the cohort, as the 
duration of embryo culture is considered an important factor affecting perinatal outcomes.109  
The Bern IVF Cohort currently includes n=319 women, with a total of n=488 pregnancies. Of the 
pregnancies n=190 ended in a miscarriage and n=298 in a delivery (272 singletons, 25 twins, 1 
triplet), with 269 singletons born alive (Table 1). (Article 1 and Article 2) 
 
Table 1: Live births per treatment in the Bern IVF Cohort (per achieved pregnancy) 
  












NC-IVF (A) 110 14 26  
 
70 (63.6%) 0 
NC-IVF (C)  
with CC 
124 21 25 1 74 (62.1%) 3 
mIVF (D) 
with CC 
25 4 2 17 (76.0%) 2 
mIVF (E) 47 10 9 1 23 (57.4%) 4 
cIVF 182 44 35 1 85 (56.0%) 16 /1 
Total  488 93 97 3 269 26 (53) 
LBR: Live birth rate including multiples; NC-IVF: Natural cycle IVF, mIVF: minimal stimulation IVF, CC: 
Clomiphene citrate, cIVF: conventional stimulated IVF 
*Perinatal death is defined as death from 28 gestational weeks until 7 days after birth 
 
Table 2: Singletons born alive by treatment scheme and year of OPU in the Bern IVF Cohort 
Treatment 2010 2011 2012 2013 2014 2015 2016 Total 
NC-IVF (A) 10 1 14 3 11 12 19 70 
NC-IVF (C) 
with CC 
5 5 9 14 9 18 14 74 
mIVF (D) 
with CC 
0 0 0 5 0 6 6 17 
mIVF (E) 2 0 2 5 5 2 7 23 
cIVF 15 17 7 7 6 12 21 85 
Total 32 23 32 34 31 50 67 269 
NC-IVF: Natural cycle IVF, mIVF: minimal stimulation IVF, CC: Clomiphene citrate,  
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2.1.2.  The Bern IVF Cohort: establishment of control group 
In 2018, the decision was made to establish a control group of spontaneously conceived children for 
comparison to the IVF children of the Bern IVF Cohort Study. The recruitment of possible controls 
was conducted through the obstetrics department of the University Women’s Hospital in Bern. 
Women coming for ultrasound in the first trimester of their pregnancy were matched with the 
mothers of singletons from the Bern IVF cohort. It was decided to only match women treated with 
NC-IVF or cIVF. A total of n=155 women were matched in a 1:3 ratio. The matching criteria were the 
age of the mother (+/- 1 year), the parity (primipara vs multipara) and the (planned) due date (+/- 6 
months). 
Exclusion criteria were the same as for ART treatment at the Bern University Women’s hospital: 
Mothers with problems of drug abuse or parents infected by human immunodeficiency virus (HIV) 
were excluded. Additionally couples, which used more than 12 months to become pregnant were 
declared as subfertile. Couples who used ART treatment to achieve the pregnancy were excluded as 
well. To identify the couples to exclude, a questionnaire was sent with the patient information and 
the informed consent form. The plan was to match 465 controls. 398 women were eligible for 
contact. A first reminder letter was sent to 255 (65.5%) women and 227 got a phone call as a second 
reminder (58.4%) Figure 1 shows the procedure for the contact of the controls. Figure 2 shows the 
population of the control group. Finally, complete data on 268 women, their pregnancies and births, 
was available.  
 
Figure 1: Contact of controls and reminders, process to retrieve informed consent 
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Lost to Follow-Up 
(n=30)




Not fulfilling inclusion criteria 
- illicit drug use (n=3)
- no live birth (n=2)
- HIV positive (n=1)
- ART / subfertility (n=30)












Not eligible for contact
- had ART (n=34)
- no live birth (n=29)
- multiple birth (n=1)
- no contact available (n=3)
 
Figure 2: Final population of the control group * either general consent or no documented refusal available at 
Inselspital. ART: Assisted reproductive technologies, HIV: Human immunodeficiency virus  
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2.2.The Swiss Infant Feeding Study 
The Swiss Infant Feeding Study (SWIFS) was the third study on the prevalence and duration of 
breastfeeding and infant nutrition in Switzerland. It was conducted by the Swiss Tropical and Public 
Health Institute at the University of Basel. It is a cross-sectional study using written postal 
questionnaires. Data was collected on social-economic status, nationality and lifestyle, alongside 
information on pregnancy and birth. Additionally, in 2014, information on employment conditions, 
child and maternal health, health-related behaviour and social networks was collected. The 
questionnaire also contained a 24-hour nutrition protocol. The Swiss Parent Counselling Services 
(Mütter- und Väterberatungsstellen) randomly recruited mothers from the German, French and 
Italian speaking regions of Switzerland. They sent a reminder two weeks after the first questionnaire. 
40% (n=1650) of the questionnaires were returned.179 
The Swiss Tropical and Public Health Institute provided the data they used to analyse breastfeeding 
duration in Switzerland during the first year of life (n=1421). It served as reference group to the 
breastfeeding data from the Bern IVF Cohort. (Article 2) 
2.3.Endometrial thickness in women after NC-IVF 
This was a retrospective cohort in which 225 women undergoing their first NC-IVF cycle were 
identified. 111 did not have subsequent embryo transfer, and nine were excluded for other reasons 
(endometriosis and TESE). In this sample of 105 women who met the inclusion criteria, the influence 
of endometrial thickness on pregnancy rates is analysed. In NC-IVF, the endometrium is not 
influenced by the hormonal stimulation of follicular growth. Research on the association between 
endometrial thickness and pregnancy rates has mostly been done on stimulated IVF cycles. (Article 3)  
2.4.Women with hysteroscopy assessment 
A cohort of 217 women who had a planned hysteroscopy assessment for different reasons between 
2014-2019 was set up at the Bern University Women’s Hospital. Women diagnosed with RIF and RPL 
usually have a hysteroscopy assessment in order to identify possible causes. 127 women did fulfil the 
definitions of repeated implantation failure and recurrent pregnancy loss. This group of women was 
used for our retrospective analysis on time-to-pregnancy and time to live birth after the diagnosis 











3. Objectives of the thesis 
The aim of this thesis is to contribute to the understanding of factors influencing pregnancy and 
perinatal outcomes after different ART treatments for infertility.  
Specific objectives included:  
1) To further develop the Bern IVF cohort by including patients treated in 2016 and setting up a 
control group of spontaneously conceived children  
2) To evaluate perinatal outcomes within the Bern IVF cohort: birthweight, gestational age and 
birthweight percentile (Article 1)  
3) To assess breastfeeding behaviour and duration of mothers with children born within the 
Bern IVF cohort in comparison to a random sample of mothers in Switzerland (Article 2) 
4) To support the understanding of CE in women with RIF and RPL and to analyse time-to-
pregnancy and live birth depending on the biopsy and subsequent treatment in cases of CE 
(Article 4) 
5) To support the research on fertility and fertility treatments and their outcomes in the 
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Abstract  30 
Aim: To investigate whether breastfeeding initiation and duration differ between women with 31 
pregnancies conceived through in vitro fertilization and women who conceived spontaneously.  32 
Methods: Breastfeeding behavior was studied using a comparative cross-sectional study 33 
design. The in vitro fertilization group included mothers who had a singleton live birth between 34 
2010 and 2016 conceived through in vitro fertilization (N=198), either with or without 35 
gonadotropin stimulation. The population-based control population (N=1421) consisted of a 36 
randomly selected sample of mothers living in Switzerland, who gave birth to a singleton in 37 
2014.  38 
Results: A total of 1619 women were included in this analysis. Breastfeeding initiation rate was 39 
similar between the in vitro fertilization group (93.4%) and control group (94.8%). No increased 40 
risk of earlier breastfeeding cessation after in vitro fertilization treatment could be found 41 
compared to the control group over the whole observational period of 12 months (HR=1.00, 95% 42 
CI 0.83-1.20, p=0.984). There was no difference in breastfeeding initiation or duration after 43 
gonadotropin stimulated in vitro fertilization compared to in vitro fertilization performed without 44 
gonadotropin stimulation. 45 
Conclusions: In Switzerland, in vitro fertilization treatments are not associated with earlier 46 
breastfeeding cessation. This result is reassuring for mothers undergoing in vitro fertilization.  47 
 48 
Keywords  49 
breastfeeding, lactation, breastfeeding duration, fertility, gonadotropins  50 
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Key Notes  51 
- Our cross-sectional study found that breastfeeding initiation and duration are not affected 52 
by in vitro fertilization.  53 
- Mothers and health care professionals who might be concerned about an adverse impact 54 
of in vitro fertilization on maternal breastfeeding ability can be reassured. 55 
- High doses of gonadotropin do not influence breastfeeding ability.  56 
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Introduction  57 
The World Health Organization (WHO) recommends exclusive breastfeeding for a minimum 58 
period of six months after delivery, and to continue breastfeeding for two years or more after the 59 
introduction of complementary food.(1) Numerous advantages of breastfeeding have been 60 
shown, not only for the health and wellbeing of the infant, but also for the mother and mother-61 
infant relationship.(2,3) These include a decreased risk of respiratory infections, as well as as a 62 
lower mean blood pressure, lower prevalence of diabetes or a decreased risk of becoming 63 
overweight in adulthood.(2,3) To support breastfeeding identification of possible influencing 64 
factors associated with unfavorable breastfeeding outcomes is crucial.  65 
Previous studies have shown a decreased probability of breastfeeding initiation and a shorter 66 
mean breastfeeding duration with infants born preterm, of low birth weight, by caesarean 67 
section, of male sex or with health issues. Maternal factors associated with breastfeeding 68 
outcomes include: maternal age (showing the longest breastfeeding duration between 30-39 69 
years of age), smoking, obesity and maternal level of education.(2,4-6)  70 
The effect of fertility treatment on breastfeeding initiation and duration has only been sparsely 71 
assessed. Subfertility and infertility treatments include in vitro fertilization (IVF) and 72 
intracytoplasmic sperm injection (ICSI), and are referred to as assisted reproductive 73 
technologies (ART).(7) ART impose substantial distress on parents.(8) Previous studies showed 74 
that ART may affect breastfeeding behavior.(6,9–13) Moreover, pregnancies after ART are 75 
associated with higher risks of small for gestational age, low birthweight, caesarean sections and 76 
preterm births.(14,15) These risk factors, especially when provoked by gonadotropin 77 
hyperstimulation, may possibly multiply the risks for disadvantageous breastfeeding 78 
behavior.(15,16) 79 
This paper aims to answer the following two questions: 80 
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First, what effectively influences breastfeeding behavior: infertility and ART treatment, or its 81 
association with adverse obstetric and perinatal outcomes, and second, what is the effect of 82 
high-dose gonadotropin stimulation on breastfeeding behavior?  83 
An American cross-sectional study, the largest to date (N=15.615), showed lower odds of 84 
breastfeeding at eight weeks postpartum among women who conceived after fertility treatment, 85 
but this difference was no longer significant after adjustment for multiples and preterm 86 
deliveries.(13) Studies with a longer observation period showed an increased risk for earlier 87 
breastfeeding cessation after fertility treatments at four (11), six (10) or eight months.(12) In 88 
adjusted analysis often other factors additionally to ART were as well influencing breastfeeding 89 
behavior such as maternal age, mode of delivery or adverse perinatal outcomes (10-13,17). On 90 
the other hand, a small Canadian study assessing breastfeeding difficulties including 76 infants 91 
conceived by ART did not show any difference to spontaneously conceived children.(18) For 92 
Switzerland, no research on breastfeeding after ART exists so far as well as on the impact of 93 
gonadotropin stimulation on breastfeeding outcomes. Given the great importance of 94 
breastfeeding for mother and child, further research in different cultural settings is needed. 95 
The aim of our study was to investigate whether breastfeeding initiation and duration in women 96 
with pregnancies after ART differs from the breastfeeding behavior of a randomly selected 97 




This is a comparison of two cross-sectional surveys about the initiation and duration of 102 
breastfeeding, with a total number of 1619 mothers of singletons included. They either had 103 
fertility treatment at the Division of Endocrinology and Reproductive Medicine at the Department 104 
of Obstetrics and Gynecology in University Hospital Bern (IVF population), or participated in the 105 
Swiss Infant Feeding Study (SWIFS population) (see Figure 1). 106 
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Population 107 
The IVF population included 198 women who had singleton live births after fertility treatment with 108 
or without hormonal stimulation followed by a fresh embryo transfer from 2010 to 2016. 109 
Fertilization was achieved either by IVF or by ICSI. Conventional IVF treatment (cIVF) was 110 
conducted according to standard agonist or antagonist protocols using ≥ 150 international units 111 
(IU) of human menopausal gonadotropin (HMG) for hormonal stimulation and urinary human 112 
chorionic gonadotropin (hCG) for ovulation induction.(15) Natural cycle in vitro fertilization (NC-113 
IVF) avoids gonadotropin stimulation to enable spontaneous follicular recruitment.(19) In NC-114 
IVF, a trigger of 5000 IU urinary hCG for ovulation induction was applied, when the follicular 115 
maturity was achieved as described elsewhere.(15,19) Women with a regular menstrual cycle 116 
chose either NC-IVF or cIVF according to their preference.(15,19)  117 
Pregnancies originating from cryopreserved embryo transfers were excluded, as were 118 
pregnancies resulting in miscarriages, perinatal deaths and multiple births.  119 
The SWIFS population (N = 1421) served as the control population. It was the third national 120 
cross-sectional study about early infant feeding within Switzerland. The survey includes mothers 121 
with infants born in 2014, randomly selected by their local parent counselling service.(2) All 122 
women with missing information on either breastfeeding initiation or breastfeeding duration were 123 
excluded for this analysis.  124 
 125 
Data collection IVF population 126 
Data on breastfeeding initiation and duration were collected using postal questionnaires. 127 
Questions were “Have you ever breastfed your baby?” (yes/no), “If ‘yes’, for how long?” and 128 
possible answers were < 1 month, 1 month, 2 months, 3 months etc. up to 12 months or > 12 129 
months. Mothers who did not initially respond were additionally contacted by phone. 130 
Demographic data, data on medical and obstetric history, information on ART treatment, 131 
pregnancy and delivery outcomes was either collected from medical records, or from the delivery 132 
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clinic. Data was collected using REDCap electronic data capture tools (REDCap 8.5.19 Vaderbilt 133 
University, Nashville, USA) hosted at the Clinical Trials Unit, University of Bern. 134 
 135 
Outcomes 136 
The primary outcomes were defined as 1) breastfeeding initiation rate and 2) duration of 137 
breastfeeding. Primary outcomes were compared between the IVF- and the SWIFS population 138 
and between mothers after IVF treatment with and without gonadotropin stimulation (NC-IVF vs. 139 
cIVF). 140 
Breastfeeding initiation was defined as receiving any breast milk after delivery (breastfed or 141 
pumped). Breastfeeding duration was defined as the period of time infants received any breast 142 
milk in addition to food or other liquids.  143 
Further factors were assessed: maternal age, level of education, smoking during pregnancy, 144 
body mass index (BMI), parity, mode of delivery, gestational age, birthweight and infants’ 145 
sex.(2,6) For the IVF population, we also assessed duration of preceding subfertility (≤24 146 
months and >24 months) and cause of subfertility (male, female or idiopathic).  147 
A high level of education was defined as graduation from an university, moderate level of 148 
education as an apprenticeship, vocational school or high school diploma and low level of 149 
education as elementary school level or below. BMI categories were defined as underweight        150 
< 18.5, overweight 25.1-29.9 or obese ≥ 30 kg/m2. For delivery data, low birth weight was 151 
defined as below 2 500g, and preterm delivery as delivery before 37 completed gestational 152 
weeks.  153 
 154 
Statistical analysis 155 
Statistical analysis was performed using Stata 16.0 (StataCorp LLC, Texas, USA). To compare 156 
groups, the Chi Square test was used for categorical variables, and univariable linear regression 157 
for continuous variables. Time-to-event analysis, using Kaplan-Meier survival estimates, was 158 
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performed to compare duration of breastfeeding between different study groups. Follow-up time 159 
started at delivery and the event of interest was the complete cessation of breastfeeding. In the 160 
SWIFS, breastfeeding duration was recorded in weeks and for the IVF population in months. 161 
This was kept for the analysis as to not lose any information. For women who did not initiate 162 
breastfeeding at all, the duration was set to 0.01. This allows the survival probabilities to reflect 163 
the true proportion of women breastfeeding at each stage. Risk of breastfeeding cessation was 164 
evaluated using multivariable Cox regression to adjust for confounding factors. Results were 165 
considered significant if p <0.05.  166 
To analyze the effect of hormonal stimulation and perinatal outcomes, three statistical models 167 
were built. The first model included important maternal characteristics (age, BMI, smoking, 168 
education) as covariate, the second focused on delivery characteristics (parity, delivery mode, 169 
gestational age) and the third included perinatal characteristics (birthweight, infant’s sex). All 170 
significant covariate from each model were introduced in the final model (smoking, BMI, 171 
cesarean section, gestational age, birthweight, infant sex). 172 
 173 
Ethics 174 
The study “Obstetric and perinatal outcome of children born after different IVF therapies (Bern 175 
IVF cohort) compared to spontaneously conceived children” was approved by the local Ethics 176 
Committee (EC Bern, 397/15) on 26 January 2016 and again on 29 August 2019 (3rd 177 
Amendment). SWIF Study was approved by the ethic commission of Basel (EC 259/13) on 178 
October 17th 2013.  179 
  180 
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Results 181 
Characteristics of study populations 182 
The population characteristics are summarized in Table 1. Mothers in the IVF population were 183 
on average 2.6 years older than SWIFS mothers smoked less often during pregnancy and had 184 
on average a lower BMI. The maternal level of education was higher in the SWIFS population, 185 
as was parity. Regarding delivery, the proportion of caesarean section was higher after IVF, but 186 
preterm deliveries did not differ.  187 
 188 
Breastfeeding initiation 189 
In both groups, a very high proportion of mothers started breastfeeding, with 93.4% among the 190 
IVF population and 94.8% among the control group (p=0.427). Overall, maternal smoking during 191 
pregnancy and increased maternal BMI were both strongly associated with lower breastfeeding 192 
initiation. 11.0% of mothers who smoked during pregnancy did not initiate breastfeeding versus 193 
only 4.7% of non-smokers (p=0.001). Mean BMI of breastfeeding mothers was 22.4 versus 23.5 194 
in mothers not breastfeeding (p=0.008). Only 4.0% of mothers with a higher level of education 195 
did not start breastfeeding compared to 7.2% of mothers with low or middle education (p=0.015). 196 
Furthermore, primiparous women were more likely to initiate breastfeeding than multiparous 197 
women (95.6% vs. 93.3%; p=0.042). Mothers after caesarean section had a higher risk of not 198 
initiating breastfeeding when compared to mothers after a vaginal delivery (92.4% vs 95.7%; 199 
p=0.006). Preterm versus term birth (89.7% vs 95.2%; p=0.014) and low versus regular 200 
birthweight (89.6% vs 94.9%; p=0.044) were important factors with a negative influence on 201 
breastfeeding initiation. Mothers with cIVF (92.6%) started breastfeeding as often as mothers 202 
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Breastfeeding duration  206 
The duration of breastfeeding did not differ between the IVF population and the SWIFS 207 
population in the first year after delivery (Figure 2). At four weeks postpartum, 92.4% of the 208 
women conceived by IVF and 88.5% of the women in the control group were still breastfeeding. 209 
Similar results were seen at 12 weeks (IVF: 81.3% vs. control: 79.7%), 24 weeks (IVF: 65.2% 210 
vs. control: 62.9%) or 32 weeks (IVF: 48.5 vs. control: 46.5). After the tenth month, 35.4% of the 211 
IVF population was still breastfeeding and 18.2% continued breastfeeding for more than a year.  212 
There was no difference between cIVF and NC-IVF for the duration of breastfeeding. Four 213 
weeks postpartum, 88.89% of the mothers after cIVF treatment were breastfeeding their infants 214 
versus 93.75% after NC-IVF. 215 
Factors significantly associated with a shorter duration of breastfeeding were maternal smoking 216 
during pregnancy, increased BMI and caesarean section. No difference could be found in 217 
breastfeeding duration between male and female infants (see Table 2).  218 
The higher the gestational age and the birthweight, the longer the babies were breastfed. 219 
Preterm birth in general was not significantly associated with shorter breastfeeding duration, but 220 
low birthweight was.  221 
In the final model after adjustment for the important influencing factors, the HR regarding IVF 222 
was not changed (see Table 2).  223 
In the subanalysis within the IVF population, the cause of infertility did not influence 224 
breastfeeding initiation or duration. If male infertility was the reason for IVF treatment, mothers 225 
were breastfeeding in 94.02% compared to 90.57% with female subfertility (p=0.553). The 226 
duration of preceding infertility ≤ 24 months had no influence on breastfeeding outcomes 227 
compared to longer duration of infertility (≤ 24 months: 93.42% vs. >24 months: 93.44%, 228 
p=0.995).  229 
 230 
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Discussion  231 
This study aimed to analyze the influence of IVF treatment on breastfeeding behavior in 232 
Switzerland by comparing a random population sample from the Swiss Infant Feeding Study to 233 
the population of the Bern IVF cohort. In Switzerland, the proportion of mothers starting 234 
breastfeeding is 95%, which is very high in comparison to other countries such as France 235 
(60.2%) or Germany (90%).(2,6,20) In our sample, breastfeeding initiation was high and at a 236 
similar level in both the IVF group and the SWIFS population sample.  237 
Our results allow us to conclude that the mode of conception does not affect breastfeeding 238 
duration – a reassuring finding for mothers and health care professionals concerned about IVF 239 
adversely affecting maternal breastfeeding ability.  240 
These findings are in line with previous studies, presenting similar breastfeeding initiation rates 241 
and breastfeeding durations when comparing mothers who conceived through any form of 242 
fertility treatments to mothers with spontaneous conceptions.(18,21–23)  243 
Of the studies cited above, only the Canadian study of O’Quinn et al. focused on breastfeeding 244 
rates, difficulties and duration as outcomes. The other three studies collected information on 245 
breastfeeding as covariates, but their focus was motherhood or aspects of the development of 246 
the child.  247 
O’Quinn et al. found that 54.1% of the infants who were conceived through intrauterine 248 
insemination, fertility enhancing drugs, IVF or ICSI (n=76), and 59.7% of the infants conceived 249 
spontaneously (n=150), were breastfed at four months postpartum and no differences existed 250 
regarding breastfeeding initiation, breastfeeding duration or breastfeeding difficulties.(18) From 251 
the studies collecting breastfeeding as covariates, an Australian study from 1997 showed no 252 
differences regarding breastfeeding behavior focusing on the psychological adjustment to early 253 
motherhood after conception by IVF (n=65, 68.8%) versus spontaneous (n=62, 74.6%) at four 254 
months postpartum.(21) A prospective cohort study from Belgium (ART: n=118, non-ART: n=59) 255 
(23), and a  cross-sectional study from France (ART: n=66, non-ART: n=33) (22), both 256 
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investigating psychomotor development in infants, found no differences in breastfeeding 257 
behavior between the two groups. 258 
A particular strength of our study is the focus on breastfeeding behavior as an outcome in a 259 
country like Switzerland. Another strength is the confirmation of previous risk factors for impaired 260 
breastfeeding. A recent meta-analysis showed a relative risk (RR) of 1.23 for caesarean section 261 
to be associated with shorter breastfeeding duration, and our study confirmed this finding (HR 262 
1.22).(17,24) Furthermore, our data confirms that the higher the gestational age (HR 0.99) and 263 
the birthweight (HR 0.99), the longer babies were breastfed, as described in previous 264 
research.(4) Women within our IVF group had a higher rate of caesarean sections and mean 265 
gestational age was lower. Both are important risk factors for shorter breastfeeding duration, 266 
especially after fertility treatment.(10,13,25) Despite the higher incidence of these risk factors in 267 
the IVF population, breastfeeding initiation and duration are not affected. This could be due to 268 
overcompensation on the part of the mother, which might be due to the strong internalized 269 
pressure of perception of failing further at motherhood. This is often reported by mothers after 270 
fertility treatments.(18,25,26) 271 
Our study further confirms influence of lifestyle and demographic factors on breastfeeding 272 
duration.(2,4,5,27) Smoking during pregnancy was associated with earlier breastfeeding 273 
cessation (HR 1.71), similar to findings of Cohen et al. (RR 1.91).(24) Our HR of 1.04 for shorter 274 
breastfeeding duration in obese women confirms what is known from a large systematic review 275 
with HR’s ranging from 1.24 to 2.54.(28) However, it is difficult to disentangle the different risk 276 
factors within the IVF group (more caesarean sections/lower gestational age), as they smoke 277 
less and have a lower BMI – both factors that positively influence breastfeeding.(24,28) As 278 
presented in the meta-analysis from Cohen et al. (RR 1.68) our results further confirm that 279 
women with a lower level of education breastfeed for a shorter time period (HR 1.48).(24)   280 
The critical factors affecting breastfeeding behavior are the same in women after IVF as after 281 
spontaneous conception, and include the perinatal health of the infant, maternal factors and the 282 
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support of the health care system. Support in early motherhood is an important factor in 283 
promoting breastfeeding.(29) In Switzerland, one third of all obstetric clinics are certified by the 284 
United Nations Children’s Fund (UNICEF) and the WHO as baby-friendly hospitals, which 285 
accounts for the high breastfeeding initiation rate.(30,31) Breastfeeding support in Switzerland 286 
further includes: discussions about breastfeeding during routine pregnancy consultations, 287 
support in breastfeeding management postnatally through nursing staff at the delivery clinic and 288 
breastfeeding support through a midwife after discharge.(2,32) These services are covered by 289 
the mandatory health insurance, which all persons have.(2,32) The mode of conception itself 290 
does not seem to influence breastfeeding behavior.   291 
However, there is also controversial literature on the effect of mode of conception.(9–292 
13,17,18,21–23) Five studies on breastfeeding following fertility treatment found differences at 293 
certain time points during the first year postpartum.(9–13) First, a large Chinese prospective 294 
cohort study (N=935) found lower breastfeeding rates at 6 months postpartum in the fertility 295 
treatment group compared to a spontaneous conception group; however, similar breastfeeding 296 
rates were found at 12 months postpartum.(10) Similarly to our study, they accounted for 297 
confounding factors such as maternal BMI or infant’s birthweight.(10) Second, a smaller Italian 298 
retrospective case-control study (N=188) found that a lower percentage of women after fertility 299 
treatment were breastfeeding at 6 weeks postpartum, compared to women who gave birth after 300 
spontaneous conception, but at 6 months postpartum breastfeeding rates no longer differed.(9) 301 
Third, similar results are reported in an Australian prospective cohort study (N=183) showing 302 
lower percentages of women breastfeeding at 6 weeks and 8 months in the ART group.(12) 303 
However, in both latter studies, small sample sizes and a single center study design limit their 304 
evidence.(9,12) Fourth, Michels et al. showed that mothers after fertility treatment were more 305 
likely to cease breastfeeding before the 12th month after birth, even after adjustment for 306 
confounders such as preterm birth.(11) In a US cohort study including 1361 women after ART, 307 
they accounted for different factors, but not for twins.(11) Contrary to the results of Michels et al. 308 
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(11), the fifth, a recent cross-sectional surveillance from the US reported lower odds of 309 
breastfeeding at 8 weeks postpartum among women who conceived through fertility treatments 310 
(n=1056), but this difference was no longer significant after adjustment for multiples and preterm 311 
birth.(13) However, breastfeeding duration was only analyzed at 8 weeks postpartum.(13) 312 
Furthermore, both US studies were unable to conclude whether a specific treatment or a 313 
combination of treatments may impact breastfeeding, as different fertility treatments were 314 
grouped together (e.g. intrauterine insemination, ovulation induction only, IVF).(11,13) Unlike 315 
previous studies, we were able to focus on breastfeeding outcomes specifically after IVF and 316 
ICSI in combination with fresh embryo transfer, by excluding fertility enhancing methods or 317 
intrauterine insemination. Furthermore, by comparing gonadotropin stimulated IVF to non-318 
gonadotropin stimulated IVF, it is possible to assess the effect of high-dose hormonal stimulation 319 
on breastfeeding outcomes. Since this comparison showed no significant impact on 320 
breastfeeding initiation and duration in our study, it is reassuring that the use of high doses of 321 
hormones does not seem to influence breastfeeding ability. 322 
The following two aspects are limitations of this study: First, the randomized sample of mothers 323 
in the SWIFS could possibly include infants conceived through fertility treatments, as the SWIFS 324 
did not collect information on mode of conception. Because only 2.5% of children born in 325 
Switzerland are generated by fertility treatments, the potential effect on our data analysis is very 326 
small.(33) Second, a selection bias cannot be ruled out, meaning that well-educated women are 327 
possibly more interested in research, and that this has subsequently led to higher participation 328 
rate in both study groups. 329 
 330 
Conclusion 331 
Three conclusions can be drawn from this study. First, in Switzerland, in vitro fertilization 332 
treatments are not associated with earlier breastfeeding cessation. Second, our results confirm 333 
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findings from other studies: infants with low gestational age, low birthweight or infants born by 334 
caesarean section are less frequently breastfed, and maternal obesity, smoking and low level of 335 
education negatively influence breastfeeding behavior. Third, in our study there is no difference 336 
in breastfeeding behavior between mothers undergoing NC-IVF compared to mothers 337 
undergoing hormonally stimulated cIVF therapy. 338 
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Table legends 461 
462 
Table 1: Characteristics of IVF population and SWIFS (Swiss Infant Feeding Study) population. 463 
Note. Values are presented as means with standard deviations or n with proportions (%). 464 
a) in vitro fertilization, b) mean, c) standard deviation, d) body mass index kg/m2, e) maternal465 
level of education was defined as follows: high (graduation from a university), moderate 466 
(apprenticeship or high school degree), low (elementary school level or below), f) preterm 467 
delivery ≤ 37 weeks, g) vacuum extraction or forceps. 468 
469 
Table 2: Multivariable Cox regression models for the duration of breastfeeding. 470 
Note. HR >1 means a higher risk for breastfeeding cessation, so shorter breastfeeding time 471 
Model I: adjusted multivariable Cox regression model with breastfeeding duration as outcome 472 
and IVF treatment as exposure adjusted for maternal characteristics 473 
Model II: adjusted multivariable Cox regression model with breastfeeding duration as outcome 474 
and IVF treatment as exposure adjusted for delivery characteristics 475 
Model III: adjusted multivariable Cox regression model with breastfeeding duration as outcome 476 
and IVF treatment as exposure adjusted for perinatal characteristics 477 
Final Model: adjusted multivariable Cox regression model with breastfeeding duration as 478 
outcome and IVF treatment as exposure adjusted for smoking, BMI, cesarean section, 479 
gestational age, birthweight and infant sex 480 
a) hazard ratio, b) confidence interval, c) maternal level of education was defined as follows:481 
high (graduation from a university), moderate (apprenticeship or high school degree), low 482 
(elementary school level or below), d) body mass index kg/m2, e) vacuum extraction or forceps, 483 
f) preterm delivery ≤ 37 weeks484 
485 
Figure legends 486 
487 
Figure 1: Study population flow-chart. 488 
489 
Figure 2: Kaplan-Meier estimates displaying the proportion of women breastfeeding over time 490 
after delivery.  491 
Up: IVF population vs SWIFS population; below: Subanalysis within IVF population 492 
89










Maternal age (years) (n=1615) 34.79 3.76 32.23 4.30 <0.001
Maternal smoking during pregnancy 5 2.53 168 11.84 <0.001
Maternal BMI (kg/m2)d (n=1563) 21.97 3.29 22.51 3.64 0.047
Maternal education in categoriesd (n=1569)
High 71 44.10 757 53.76
0.003Moderate 89 55.28 600 42.61
Low 1 0.62 51 3.62
Fertility status
Parity (n=1607)
Primiarous 157 79.29 751 53.30 <0.001Multiparous 41 20.71 658 46.70
Delivery details
Gestational age (days) (n=1533) 274.59 13.02 276.23 12.37 0.085
Gestational age in categories
187 94.44 1239 92.81
0.04733-37 gestational weeks 9 4.55 87 6.5229-32 gestational weeks 1 0.51 9 0.67
24-28 gestational weeks 1 0.51 0 0.00
Preterm birthf (n=1542) 11 5.56 96 7.14 0.412
Delivery mode (n=1619)
Spontaneous vaginal delivery 80 40.40 843 59.32
<0.001Instrumental vaginal deliveryg 28 14.14 159 11.19
Caesarean Section 90 45.45 419 29.70
Infant
Birthweight (grams) (n=1588) 3274.99 580.12 3321.16 505.99 0.239
Birthweight in categories
Normal 186 93.94 65 4.68 0.396Low 12 6.06 1325 95.32
Infant sex




Table 2. Multivariable Cox regression models for the duration of breastfeeding
Unadjusted HRa  
(95% CIb) (for each 
covariate individually) P value
Model I        .    
Adjusted for maternal 
characteristics
HRa (95% CIb) P value
Model II      .
Adjusted for delivery 
characteristics
HRa (95% CIb) P value
Model III    .. 
Adjusted for perinatal 
characteristics 
HRa (95% CIb) P value
Final model
Adjusted
HRa (95% CIb) P value
In vitro fertilization 1.00 (0.83 – 1.20) 0.984 1.04 (0.85 – 1.28) 0.698 0.96 (0.80 – 1.16) 0.695 1.00 (0.83 – 1.21) 0.968 1.05 (0.87 – 1.27) 0.615
Maternal demographics
Maternal age (years) 0.98 (0.97 – 1.00) 0.054 0.99 (0.98 – 1.01) 0.438
Maternal educationc
High 1.00 1.00
Moderate 1.41 (1.23 – 1.62) <0.001 1.31 (1.13 – 1.52) <0.001
Low 1.83 (1.25 – 2.67) 0.002 1.48 (0.97 – 2.25) 0.067
Maternal factors 
Smoking during pregnancy (yes/no) 1.68 (1.37 – 2.06) <0.001 1.60 (1.30 – 1.99) <0.001 1.71 (1.38 – 2.13) <0.001
BMI (kg/m2)d 1.04 (1.02 – 1.06) <0.001 1.05 (1.03 – 1.07) <0.001 1.04 (1.02 – 1.03) <0.001
Fertility status 
Parity (continuous) 0.93 (0.84 – 1.02) 0.108




Spontaneous vaginal delivery 1.00 1.00
Instrumental vaginal deliverye 1.12 (0.91 – 1.39) 0.276 1.13 (0.91 – 1.40) 0.287
Caesarean section 1.29 (1.11 – 1.50) 0.001 1.30 (1.12 – 1.51) 0.001
Caesarean section (yes/no) 1.27 (1.10 – 1.46) 0.001 1.22 (1.04 – 1.41) 0.012
Perinatal
Gestational age (days) 0.99 (0.98 – 0.99) 0.001 0.93 (0.99 – 1.00) 0.093 1.00 (0.99 – 1.00) 0.299
Gestational age in categories
1.00
33-37 gestational weeks 1.06 (0.79 – 1.43) 0.680
29-32 gestational weeks 1.24 (0.55 – 2.76) 0.606
24-28 gestational weeks 2.05 (0.29 – 14.56) 0.474
Preterm birthf 1.09 (0.83 – 1.44) 0.536
Birthweight (grams) 1.00 (1.00 – 1.00) 0.003 1.00 (1.00 – 1.00) 0.166 1.00 (1.00 – 1.00) 0.086
Birthweigth in categories
Normal 1.00
Low (< 2’500g) 1.37 (1.02 – 1.84) 0.034
Infant sex 
Female 1.00 1.00 1.00





IVF sample for breastfeeding analysis (n=198)
- natural cycle IVF (n=112)
- conventional gonadotropin stimulated IVF (n=86)
SWIFS population 
(n=1650)
- no consent for follow-up data (n=23)
- missing information on breastfeeding (n=48)
IVF singleton live births
(n=269)
- multiple pregnancies (n=26)
- perinatal death (n=3)
- lost to follow-up (n=1)
SWIFS sample for breastfeeding analysis
(n=1421)
- incomplete questionnaire (n=1)
- multiple pregnancies (n=70)
- date of birth missing (n=18)
- age of child > 12 months (n=114)
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Thin Endometrium Is Also Associated
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Introduction: Does the endometrial thickness (EMT) at the time of follicle aspiration
correlate with the pregnancy rate in unstimulated menstrual cycles?
Materials and Methods: This is a retrospective, observational single center study.105
women with regular menstrual cycles undergoing their first NC-IVF cycle with an embryo
transfer were analyzed. Clinical pregnancy and live birth rates were calculated and data
were adjusted for women’s age, cycle day of follicle aspiration and body mass index
(BMI).
Results: Age of participants was 35.0 y [32.0; 37.0]. Follicle aspiration was performed on
day 14.0 [12.0; 15.0] of the cycle. Total clinical pregnancy rate was 24.8% and live birth
rate 15.2% per transfer. Pregnancy rate in women with endometrial thickness ≤7mm
(n = 27) was 7.4 and 30.8% in women >7mm (n = 78) (OR 5.56, 1.22–25.36) (P
= 0.03). Live birth rates were not significantly different. Quadratic regression analysis
revealed lower pregnancy rates in women with thin (around <8mm) as well as with thick
(around>11mm) endometria. P-value after crude quadratic analysis was 0.028 and after
adjustment for age, day of aspiration and BMI was 0.039. Significance was not reached
for live birth rates.
Conclusion: Thin endometrium should also be considered as an independent negative
prognostic factor for achieving pregnancy in women without ovarian stimulation.
Keywords: endometrium, pregnancy rate, live birth rate, natural cycle IVF, spontaneous cylce
INTRODUCTION
The importance of the endometrium for the development and maintenance of pregnancy is
clearly proven. However, it is unclear which endometrial factors are of relevance (1). Histological
examination in couples who wish to conceive makes little sense as a biopsy would be necessary.
In transvaginal ultrasound evaluation endometrial thickness, the echo pattern and endometrial
perfusion are evaluated (2). Ultrasound analysis of endometrial thickness (EMT) is most commonly
performed, as this is the easiest and best reproducible technique.
97
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The significance of the endometrial thickness has been
investigated in numerous studies and in meta-analyses. The
investigations are essentially limited to in vitro fertilization
treatments (IVF) with high-dose stimulation therapy and
intrauterine insemination treatment (IUI) with different ovarian
stimulation regimes.
In IVF treatments, a thin endometrium is associated with
lower pregnancy rates. The clinical pregnancy rate is related
to a lower chance of pregnancy if endometrial thickness is
≤7mm (OR 0.42, 95% CI: 0.27, 0.67) (3). The data regarding a
thick endometrium is not so clear. A previous study described
reduced pregnancy rates in women with endometrium >14mm
(4), whereas other studies did not find decreased or found even
increased pregnancy rates (5–7).
In women undergoing IUI with low dose stimulation, such a
relationship does not appear to exist. In a recent meta-analysis
with IUI treatments combined with a gonadotrophin, clomifene
citrate, or aromatase inhibitor stimulation, there was no evidence
of a difference in EMT between women who conceived and
women who did not conceive (MDrandom: 0.51, 95% CI: −0.05,
1.07) (8).
Because ovarian stimulation treatments were used, the results
of these studies cannot be transferred to the unstimulated
situation. As a result, the study findings have only limited use
in a fertility work-up for infertility to assess the relevance of the
endometrium as a cause of sterility.
Based on this, we investigated the pregnancy rate as a function
of the endometrial thickness using the Natural Cycle IVF (NC-
IVF) model, in which no ovarian stimulation except ovulation
induction with human chorionic gonadotropin, hCG, and luteal
phase progesterone supplementation was administered.
Since strict inclusion and exclusion criteria such as the
transfer of only one embryo were defined and thus numerous
confounders on the pregnancy rate could be excluded, this may
be the first study which also allows a cautious estimate of the
importance of endometrial thickness for a pregnancy event in a
spontaneous cycle.
METHODS
Study Population and Participants
The retrospective, observational single center study was
performed between 2011 and 2016. A total of 225 women, 18–42
years of age with regular menstrual cycles (24–32 days) and
basal FSH concentrations <10 IU/L undergoing their first IVF
cycle treatment with transfer of a single embryo were screened.
Women had been offered both, NC-IVF and conventional IVF
but decided themselves which therapy they preferred. Women
without a transfer, with endometriosis >rAFS II◦ (revised
American Fertility Society) (as diagnosed by laparoscopy or
clinical and ultrasound analysis), with fibroids as diagnosed
by ultrasound or in case ultrasound was not conclusive by
hysteroscopy and with sperm collection by testicular sperm
extraction (TESE) were excluded.
NC-IVF patients were monitored using ultrasound and
analysis of luteinizing hormone (LH) and E2 concentrations.
When the follicle diameter reached at least 18mm and the E2-
concentration was expected to be ≥800 pmol/L, 5000 IU of
hCG (Pregnyl R©, MSD Merck Sharp & Dohme GmbH, Lucerne,
Switzerland) were administered and patients were scheduled 36 h
later for oocyte retrieval. EMT was measured at the time of
oocyte aspiration by different physicians and different ultrasound
machines. Endometrium thickness was measured in mmwithout
decimal numbers in our clinical routine as intraindividual
and interindividual variations did not justify a more precise
measurement. Follicles were aspirated without anesthesia and
without analgesia using 19G single lumen needles (220 mmHg)
as described elsewhere (9). After aspiration, follicles were flushed
and aspirated 3 times each using 2–5ml flushing medium
with heparin (SynVitro
R©
Flush, Origio, Berlin, Germany). The
flushing volume was adapted according to the size of the follicles.
Fertilization was achieved by standard ICSI in all cases. Embryos
were transferred on day 2 or 3 after aspiration as long term
culture was not required with only one embryo. Women received
luteal phase support with vaginal micronized progesterone. EMT
at the time of follicle aspiration as well as biochemical and clinical
(defined as ultrasound detection of an amniotic sac) pregnancy
rates and live birth rate were analyzed per embryo transfer.
The study was carried out in accordance with the
recommendations of the local ethical committee of the IRB
Internal Review Board, Inselspital Bern on October 12th 2012
(IRB 12–223). All subjects gave informed written consent in
accordance with the Declaration of Helsinki.
Statistical Analysis
Endometrial thickness was first considered as a categorical
variable and therefore women were divided into two endometrial
thickness groups (≤7mm vs. >7mm). Patients’ baseline
characteristics were compared for quantitative variables by using
the t-test, or if normality assumption was not satisfied, by non-
parametric Wilcoxon-test. For qualitative variables (cause of
infertility), the Chi-square test was used or by Fisher’s exact test
when the sample size was small.
Clinical pregnancy and life birth rate where compared using
a logistic regression. For each outcome, we first assessed the
crude (unadjusted) association between EMT categories and the
outcome. We then adjusted the model for potential confounders
by including women’s age, day of follicle aspiration and BMI
in the model. The cause of the infertility was not considered
as we had been shown in another, not yet published, study,
that the cause of infertility is not a prognostic factor in NC-
IVF. Endometrial thickness was then considered as a continuous
variable and its effect on pregnancy and on live birth was further
analyzed using logistic regression. For each outcome, we first
assessed the crude (unadjusted) and adjusted association between
EMT and the outcome, using endometrial thickness as a linear
term. Then, we examined the linearity of the effect of EMT on
the outcomes by fitting a crude and adjusted quadratic regression
model and by testing whether the addition of a quadratic
term significantly increased the fit of the model. Models were
compared using likelihood ratio tests. P-value and the confidence
interval of models parameters were estimated using the normal
approximation.
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RESULTS
Two hundred and twenty five women undergoing a NC-IVF
cycle were identified. One hundred and eleven women (49.3%)
were excluded due to missing transfer (premature ovulation 14%,
aspirations without oocyte 15%, oocytes without fertilization
or arrested embryo growth 16%), 5 women (2.2%) due to
endometriosis, and 4 women (1.8%) due to TESE, resulting in 105
women to be included in the analysis. Cycles and transfers were
not canceled due to thin endometrium. The basic characteristics
of these women are shown in Table 1. Age of participants was
35.0 y [32.0; 37.0], cycle day of follicle aspiration was 14.0
[12.0; 15.0] and duration of infertility was 3.00 y [2.00; 4.00].
Infertility factors were severe male factor (sperm < 5 Mill/ml)
(n = 26, 24.8%), moderate and mild male factor (sperm 5- <
15 Mill/ml or total motility <40%) (n = 24, 22.9%), tubal factor
(peritubal adhesions, blockage of one or both fallopian tubes),
endometriosis rAFS I-II◦ and mixed factors (n= 22, 21.0%), and
idiopathic infertility (n= 33, 31.4%).
Overall AMH concentrations were 12.0 pmol/l [6.0; 22.0].
Clinical pregnancy rate and live birth rate as a function of
endometrial thickness are shown in Figures 1, 2. Endometrial
thickness was 6mm in 6 women, 7mm in 21, 8mm in 31, 9mm
in 17, 10mm in 15, 11mm in 9, 12mm in 5, and 16mm in 1
woman.
The pregnancy rate was firstly compared in women with
endometrial thickness ≤7mm (n = 27) vs. >7mm (n = 78).
The groups did not differ regarding women’s age, cycle day of
aspiration, duration of infertility, BMI and cause of infertility
(Table 1). Clinical pregnancy rates in women with endometrial
thickness ≤7mm (n = 27) vs. >7mm (n = 78) were 7.4 and
30.8%, respectively.
Crude and adjusted logistic regression, adjusted for women’s
age, day of follicle aspiration and BMI, showed an increased
odds of pregnancy in patients with increased endometrial
thickness >7mm (crude OR 5.56, 95% CI: 1.22–25.36, p =
0.027; adjusted OR 5.50, 95% CI: 1.14–26.62, p = 0.034).
Likewise, the odds of live birth was also increased in patients
with increased endometrial thickness, however, associations
were not significant (crude OR 6.19, 95% CI: 0.78–49.27,
p = 0.085; adjusted OR 5.98, 95% CI: 0.74–48.56, p =
0.094).
We also used endometrial thickness as a continuous variable
in logistic models. There is a not significant trend of a linear
relationship between continuous endometrial thickness and
pregnancy [crude OR (per log (mm)): 6.63, 95% CI: 0.61–71.99,
P = 0.12]; adjusted OR [per log (mm)): 4.52, 95% CI: 0.38–
53.14, P = 0.23]. Likewise, there is a non-significant trend
of a linear, non-significant relationship between continuous
endometrial thickness and live birth [crude OR (per log (mm)):
8.99, 95% CI: 0.54–150.06, P = 0.13]; adjusted OR [per log
(mm)): 8.02, 95% CI: 0.41–157.41, P = 0.17]. However, the
model fit is better whenmodeling a quadratic relationship instead
of a linear relationship between endometrial thickness and
clinical pregnancy (p-value from a model comparison = 0.03).
The crude and adjusted quadratic models indicate a decreased
odds of pregnancy for thinner (around <8mm, n = 27) but
also for very thick (around >11mm, n= 5) endometrium (p-
value for quadratic relationship: crude p = 0.028; adjusted p =
0.039).
Likewise, there was also a trend of a better model fit when
modeling a quadratic relationship between endometrial thickness
and live birth (p-value from a model comparison = 0.08). The
crude and adjusted quadratic models indicate a decreased odds
of pregnancy for thinner but also for very thick endometrium (p-




This study described for the first time the association of
pregnancy rates with endometrial thickness in unstimulated
menstrual cycles with fresh embryo transfers. The evaluation was
adjusted for the main factors that could influence the chance of
pregnancy (age) (10) and the EMT (day of aspiration and BMI)
(11).
Strengths and Limitations
To minimize the influence of possible influencing variables,
the investigation was carried out using 105 NC-IVF cycles,
in which–as in almost all NC-IVF cycles–only one embryo
was transferred. Different numbers of embryos would not have
allowed a comparison of pregnancy rates. However, it needs to be
noted that first we performed a retrospective analysis and second
that the strict inclusion and exclusion criteria resulted in a limited
number of participants. This might be a reason why significance
was only reached for pregnancy but not for live birth rate.
Endometrium thickness was analyzed by several physicians
using different ultrasound machines. Therefore, and due
to the intra und interindividual variations of endometrial
measurements, EMT was analyzed without decimal numbers,
which could have affected the precision of the analysis.
We defined the ultrasound detection of an amniotic sac as
a clinical pregnancy, which might explain the high miscarriage
rate. However, the miscarriage rate could not be allocated to a
specific endometrial thickness.
Interpretation
In all studies published to date, the association of endometrial
thickness with pregnancy rate was performed only with high-
dose IVF stimulations, cryopreserved embryos (12) or low-dose
IUI stimulations. The IVF studies suggested an increase in the
pregnancy rate with an endometrium >7mm (3), whereas the
IUI studies failed to demonstrate such a relationship (8). Our
study confirmed the reduced pregnancy rate in gonadotrophin-
stimulated IVF therapies with an endometrial thickness of
≤7mm. However, an increase in the pregnancy rate in a
particularly thick endometrium of >11mm (6), >13mm (5),
or >14mm (7), as demonstrated with gonadotrophin-stimulated
IVF therapies, could not be confirmed. In contrast, we even
observed a tendency to lower pregnancy rates in women with
particularly thick endometrium. In IUI treatments with low dose
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TABLE 1 | Baseline characteristics of all analyzed patients (n = 105) and of women with endometrial thickness ≤7mm (n = 27) vs. >7mm (n = 78) (data are shown as
median and upper and lower quartile ranges).
Total (n = 105) EMT ≤7mm (n = 27) EMT >7mm (n = 78) P-value
































Cause of infertility (n, %) 0.98
Severe male factor 26(24.8%) 7(25.9%) 19(24.4%)
moderate/mild male factor 24(22.9%) 6(22.2%) 18(23.1%)
Tubal factor, endometriosis rAFS
I-II◦ and mixed factors
22(21.0%) 5(18.5%) 17(21.8%)
Idiopathic 33(31.4%) 9(33.3%) 24(30.8%)








FIGURE 1 | Clinical pregnancy (not hatched) and live birth (hatched) rates as a function of endometrial thickness. The bar width is proportional to the number of
women in each category.
gonadotrophin stimulation, neither an increased nor a reduced
pregnancy rate (8) was found.
The reason for the reduced pregnancy rates in patients
undergoing gonadotrophin-stimulated IVF therapies with an
endometrial thickness ≤7mm compared to an endometrial
thickness >7mm is unclear. It has been speculated
that basal layer endometrial oxygen concentrations are
increased in patients with a thin endometrium, which
might be detrimental for embryo implantation (13).
It was further speculated that embryos developing in
vitro are especially susceptible to this higher oxygen
exposure (8).
In hormone-stimulated IUI treatments, there is no significant
correlation between the endometrial thickness and the pregnancy
rate (8). As a possible reason for this, it was discussed that
embryos develop more robustly in vivo and are less susceptible
to high oxygen exposure (8). However, this explanation is purely
hypothetical. Therefore, it could be speculated that in hormone-
stimulated IUI treatments a thin endometrium is associated with
lower pregnancy rates, but that this association could not be
Frontiers in Endocrinology | www.frontiersin.org 4 December 2018 | Volume 9 | Article 776
100
von Wolff et al. Endometrium in Unstimulated Cycles
FIGURE 2 | Clinical pregnancy rate (not hatched) and live birth (hatched) rates in women with endometrial thickness ≤7mm vs. >7mm. The bar width is proportional
to the number of women in each category.
detected. In the meta-analysis by Weiss et al. (8), the primary
analysis showed a significantly thinner endometrium in women
who did not conceive (MD: 0.48, 95% CI: 0.18, 0.77). The
significance was only lost when the calculation was performed
using a random effects model (MD random: 0.51, 95% CI:−0.05,
1.07) which was chosen due to the heterogeneity of studies.
This raises the question of whether a thin endometrium is
also associated with lower pregnancy rates in stimulated IUI
treatments; however, this association could not be detected due
to the heterogeneity across the studies.
Pregnancy rates have also been studied in modified natural
cycles with frozen-thawed embryo transfers (12). Mean
endometrial thickness did not differ between patients achieving
ongoing pregnancy and those who did not. However, the
pregnancy rates in women with endometrium of <7mm (n =
41) was only 9.8% whereas in women with an endometrium
of ≥7mm it was 21.0% (12). Even though the differences were
not statistically different, these data support the hypothesis, that
pregnancy rates are lower in women with thin endometrium,
even in unstimulated cycles.
Lower pregnancy rates with a thin endometrium in
unstimulated cycles are unlikely to be biologically plausible. It
is unlikely that a tendency toward a thin endometrium could
be inherited if it significantly affected fertility. There are, of
course, numerous factors that lead to a thin endometrium or
which are associated with a thin endometrium and lower the
chances of pregnancy. The most relevant factors are multiple
curettages (14) and exposure of the uterus to radiation (15).
However, these factors are either iatrogenic or due to an acquired
pathology and therefore cannot explain the reduced pregnancy
rates with a thin endometrium as described in other studies. In
our study only 1/6 (16.7%) of the women with an endometrial
thickness of 6mm and 4/21 (19.0%) with an endometrial
thickness of 7mm had undergone a curettage and none an
uterine radiation. Accordingly a curettage could be a reason for a
thin endometrium is a few women but not in the majority.
On the other hand, the question arises of how relevant a
reduced pregnancy rate with a thin endometrium really is. Of
the 6 non-pregnant women in our study with an endometrial
thickness of 6mm, 3 women became pregnant later on. Thus, the
clinical relevance of a thin endometrium without a recognizable
cause such as multiple curettages etc., is questionable.
If a patient’s endometrium is very thin, and if this may
be a possible cause of infertility, the question of possible
therapeutic options arises. Stimulation with estrogens can hardly
be carried out in a spontaneous cycle, since high estrogen
concentrations reduce FSH release and inhibit folliculogenesis
and also impair endometrial function (16). Santamaria et al. (17),
developed a treatment with bone marrow-derived stem cells,
which seems to increase the chances of pregnancy in refractory
Asherman’s syndrome and endometrial atrophy. Whether such
a complex and still experimental therapy is useful in cases with
physiologically thin endometrium is questionable, since in such
cases the endometrium is thinner but presumably functionally
intact.
The differences in studies regarding the effect of a thick
endometrium on the pregnancy rate are contradictory. In the
gonadotrophin-stimulated IVF studies, a thick endometrium
appears to be associated with a higher pregnancy rate (5–
7). However, such a dependence could not be demonstrated
in hormone-stimulated IUI therapies (8). We even found a
tendency toward a reduced pregnancy rate. However, it needs to
be noted that this finding is based on a statistical model which
only provides a very vague tendency toward a lower pregnancy
rate with very thick endometrium. Furthermore, the thickness
which leads to decreased pregnancy rates cannot be defined.
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The differences of the studies are barely explainable. It possibly
concerns physiologically different endometrial function and IVF
activity states, which do not allow a comparison of the different
treatments as the endometrium is likely to be more proliferated
and oedematous with gonadotrophin stimulation. It is also
possible that the differences are due to the low number of patients
in our study which can be considered a weakness of our study.
Since the inclusion and exclusion criteria were very strict to
be able to examine a patient population as homogeneously as
possible, the patient numbers are limited.
In conclusion, the study confirmed that thin endometrium
is also associated with lower pregnancy rates in unstimulated
cycles. Therefore, thin endometrium should be regarded as an
independent prognostic factor for achieving a pregnancy.
However, as the pregnancy rate in women with thin
endometrium is not zero but only reduced, thin endometrium
should not be regarded as an infertility but rather as a
fertility-reducing factor.
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Abstract  36 
Introduction 37 
Research has suggested that chronic endometritis is associated with repeated implantation 38 
failure and recurrent pregnancy loss. However, standardized diagnostic procedures to detect 39 
chronic endometritis and its treatment are still controversially discussed. We therefore aimed 40 
to analyse the effect of endometrial diagnostic biopsy and subsequent antibiotic treatment in 41 
case of chronic endometritis on time to live birth.   42 
Materials and Methods 43 
We conducted a historical cohort study (January 2014 – December 2018) at our University 44 
based infertility center including subfertile women (n=108) with repeated implantation failure 45 
and recurrent pregnancy loss as indications. We excluded women with relevant pathologies 46 
for mentioned indications according to international guidelines. 67 women (62%) had an 47 
endometrial diagnostic biopsy with immunohistochemically staining for CD138 to detect 48 
plasma cells from 2016-2018 (biopsy group), whereas the 41 women treated from 2014-2016 49 
only had an office hysteroscopy (reference group). If ≥ 1 plasma cell was detected, women 50 
were diagnosed with chronic endometritis and treated with doxycycline 100 mg twice a day 51 
orally for two weeks. We performed survival analysis (Kaplan-Meier) and Cox regression 52 
stratified for indication.  53 
Results  54 
Biopsy group and reference group did not differ regarding patient`s characteristics. The 55 
indications, repeated implantation failure and recurrent pregnancy loss, did not substantially 56 
impact the outcome in sensitivity analysis. Women in the biopsy group had higher chances for 57 
a pregnancy (hazard ratio 2.28; 95% confidence interval 1.23-4.24; P = 0.009) and for a live 58 
birth (hazard ratio 2.76; 95% confidence interval 1.30-5.87; P = 0.008) compared to women 59 
of reference group. Within the biopsy group, overall live birth rate tended to be slightly higher 60 
in the 42 (63.0%) women diagnosed and treated for chronic endometritis compared to 25 61 
(37%) women without chronic endometritis (live birth: hazard ratio 1.75; 95% confidence 62 
interval 0.57-5.38; P = 0.327). 63 
Conclusions 64 
Diagnostic intervention such as endometrial biopsy with subsequent antibiotic treatment in case 65 
of chronic endometritis in women with repeated implantation failure and recurrent pregnancy 66 
loss shortens time-to- live birth, suggesting the procedure to be beneficial.  67 
  68 
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Keywords  69 
Endometrial diagnostic biopsy/ chronic endometritis / recurrent pregnancy loss / repeated 70 
implantation failure / plasma cell / time-to-pregnancy/ time to live birth 71 
 72 
Abbreviations 73 
CE, Chronic endometritis 74 
CEneg, group of women with negative diagnosis of chronic endometritis 75 
CEpos, group of women with positive diagnosis of chronic endometritis 76 
CI, 95% Confidence interval 77 
HR, Hazard ratio 78 
IVF, In vitro fertilisation 79 
RPL, Recurrent pregnancy loss 80 
RIF, Repeated implantation failure 81 
HSC, Hysteroscopy 82 
 83 
Key message 84 
Diagnostic endometrial biopsy with subsequent antibiotic treatment in case of chronic 85 
endometritis (≥1 plasma cell) is associated with a shorter time-to-pregnancy and time to live 86 
birth compared to hysteroscopy assessment in women with recurrent pregnancy loss or 87 
repeated implantation failure.   88 
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Introduction 89 
Repeated implantation failure (RIF) and recurrent pregnancy loss (RPL) impose a heavy 90 
burden on women desiring children, especially when etiology remains unclear. Implantation 91 
failure has been identified by the European society of human reproduction and embryology as 92 
one of the main unresolved issues in reproductive medicine.  93 
Known risk factors for RIF and RPL are parental age, obesity, environmental exposure 94 
(including smoking and alcohol), genetic factors, uterine malformations or pathologies and 95 
thyroid autoimmunity. (1–3) Additionally, antiphospholipid syndrome is a risk factor for 96 
RPL. (3) Work-up according to guidelines includes not only ultrasound examination, but also 97 
diagnostic hysteroscopy.  98 
In RIF the transfer of an embryo following in-vitro fertilization (IVF) treatment fails 99 
repeatedly to reach a stage of clinical pregnancy (more than three good quality blastocysts/ six 100 
good quality cleavage stage embryos). (4) The World Health Organization defines RPL as 101 
three or more consecutive miscarriages; it affects from 1% to 5% of women. (2,5,6)  102 
Chronic endometritis (CE) is often subtle and asymptomatic, or it presents with atypical 103 
symptoms such as pelvic pain, vaginal discharge, abnormal bleeding, dyspareunia, and 104 
leucorrhea. While there is no doubt that CE is of high importance clinically, there is still no 105 
universally accepted definition, standardized diagnostic procedure, or treatment confirmed by 106 
randomized clinical trials.(7–9) The prevalence of CE in women with RIF reported in 107 
published studies ranges from 14.0%  up to 67.5%; the prevalence of CE in women with RPL 108 
from 9.3% up to 67.6%.(7) It is unclear if this differences in prevalence result from 109 
differences in study populations, prevalence of different pathogens or diagnostic assessment 110 
techniques. (10)  111 
By hysteroscopy (HSC) CE can be suspected by the presence of mucosal edema, focal or 112 
diffuse endometrial hyperemia, and micro polyps (<1mm). (11,12) The diagnosis should be 113 
confirmed by an endometrial biopsy stained immunohistochemically with Syndecan-1 for 114 
plasma (CD138) cells.(10,13,14) A meta-analysis showed higher pregnancy and live birth 115 
rates after antibiotic treatment for plasma cell positive chronic endometritis in women with 116 
repeated implantation failure.(15) This was also found in a meta-analysis of trials on 117 
endometrial scratch injury in women who had two or more implantation failures.(16)  118 
Overall, the impact of chronic endometritis and its treatment on pathologies like RIF and 119 
RPL, which are both affected by endometritis is still not clear. As chronic endometritis seems 120 
to affect implantation and the early pregnancy, the most relevant outcome parameter would be 121 
live birth rate, or even better time to live birth. 122 
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Accordingly, the aim of our study was to focus on the effect of endometrial diagnostics and 123 
treatments on time-to-live birth by using the method of survival analysis (Kaplan-Meier) n 124 
women undergoing hysteroscopy for both, RIF or RPL  125 
 126 
Materials and Methods 127 
Population 128 
We screened retrospectively all women treated at our center for RIF or RPL between January 129 
2014 and December 2018. We defined RIF as a failure to achieve a pregnancy after the 130 
transfer of six or more cleavage-stage embryos.(4) For RPL we used the WHO definition of 131 
≥3 recurrent pregnancy losses. (2,5)  132 
Screening work-up consisted of: thyroid function and antibody testing, exclusion of 133 
antiphospholipid syndrome and assessment of the uterine cavity by ultrasound. Consecutively 134 
we defined the following inclusion criteria for our study: women undergoing HSC or HSC 135 
and biopsy, age 42 years at HSC, body mass index (BMI) between 18 and 35 kg/m2, and a 136 
regular uterine anatomy, assessed with transvaginal ultrasound or hysterosalpingosonography. 137 
As exclusion criteria, we defined according to guidelines, the following conditions known to 138 
be associated with RIF and RPL: parental chromosomal abnormalities, sperm retrieved by 139 
testicular sperm extraction, or severe thyroid dysfunction. We did not exclude other 140 
thrombophilic conditions with the exception of antiphospholipid syndrome in women with 141 
RPL (Figure 1).(17,18) 142 
 143 
Diagnosis and histological assessment of chronic endometritis 144 
Before we conducted HSC, we ruled out chlamydia (Chlamydia trachomatis) and gonorrhea 145 
(Neisseria gonorrhoeae) with PCR from cervical-vaginal swabs. We performed the HSC and 146 
biopsy during late follicular phase, in an outpatient setting without anesthesia. For HSC we 147 
used a rigid 30° view 2·9 mm diameter hysteroscope with an atraumatic tip (TROPHYscope; 148 
Karl Storz, Tuttlingen Germany). We did not provide preoperative analgesia, sedation, or 149 
antibiotics, but cervical preparation with dequalinium chloride (Fluomizin®). We documented 150 
the appearance of the uterine cavity and the endometrium with photos (Figure 2). At the end 151 
of the exam, we performed an endometrial biopsy using a flexible biopsy device (Pipelle) and 152 
we conserved endometrial tissue in 10% formaldehyde solution. We immunohistochemically 153 
stained the sections of the paraformaldehyde-fixed paraffin-embedded endometrial biopsy 154 
samples with a monoclonal antibody against CD138, a specific marker for plasma cells 155 
according to routine protocols (Figure 2). Formalin-fixed paraffin-embedded slides with a 156 
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thickness of 3μm were pretreated with heat (95°C, 20 minutes) and then incubated with the 157 
CD138 antibody (Serotec, Cologne, Germany) in EDTA buffer at pH 9 for 15 minutes at a 158 
dilution of 1:1600, with diacetylbenzene serving as the chromogenic agent. We 159 
counterstained with hemalaun-eosin (HE) to compare the two diagnostic methods. For the 160 
diagnosis of CE as defined within this study, we relied on immunohistochemistry, considering 161 
n≥1 plasma cell per whole-slide tissue section (one plasma cell in the hotspot) as sufficient for 162 
the diagnosis of CE.(11) Before 2016 HSC without biopsy was the standard diagnostic 163 
intervention in women with RPL or RIF, these women served as historical controls.   164 
 165 
Treatment of chronic endometritis 166 
Women diagnosed with CE according to immunohistochemistry were treated with 167 
doxycycline 100 mg twice daily for two weeks. Women with an intolerance to doxycycline 168 
received ciprofloxacin 400 mg daily for two weeks. We did not perform a test-of-cure. In case 169 
of recurrent pregnancy loss after treatment, the women were re-biopsied and retreated with 170 
ciprofloxacin as a second-line treatment, as described above.  171 
 172 
Fertility treatment 173 
For women with RIF, IVF treatment was started again after biopsy, one month after 174 
termination of antibiotic therapy, or when the couple felt ready. The subsequent IVF cycles 175 
were conducted either as natural IVF cycle (19) or as conventional gonadotropin-stimulated 176 
IVF, either in an agonist or antagonist protocol. We provided luteal phase support using 177 
progesterone for up to 12 weeks of gestation.(20) For women with RPL we provided vaginal 178 
micronized progesterone 200 mg per day in the subsequent pregnancy.(21,22) 179 
 180 
Statistical analysis 181 
We compared the women from the biopsy group to the women who had HSC only, the 182 
reference group. For subgroup analysis we subdivided the women with biopsy according to 183 
the immunohistochemically diagnosis of plasma cells with CE; biopsy without diagnosis of 184 
CE (CEneg) and biopsy with diagnosis of CE (CEpos). We compared baseline characteristics 185 
and outcomes (pregnancy rates, live birth rates, time-to-pregnancy, and time to live birth 186 
among the biopsy and the reference group and between RIF and RPL. We used chi-squared 187 
test for categorical variables and univariable linear regression for continuous outcomes. For 188 
the time-to-event analyses, follow-up time started at the date of HSC or biopsy (biopsy is 189 
performed during HSC). The follow-up time ended at the event of interest or at last contact 190 
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date recorded for each woman; the event of interest is either the date of clinical pregnancy 191 
confirmed by ultrasound display of an amniotic cavity (time-to-pregnancy) or the delivery 192 
date (time to live birth). We used survival analysis (Kaplan-Meier) to compare time-to-193 
pregnancy and live birth or expected live birth between the groups. In further comparisons, 194 
we used multivariable Cox regression models including the following information: age of the 195 
women (continuous) and parity (parous vs nulliparous). We stratified Cox regression models 196 
for RIF and RPL women allowing for different baseline hazards via separate risk set 197 
definitions in the RIF and RPL group. In a sensitivity analysis, we conducted separate Cox 198 
regressions for women with RIF and women with RPL and among the two subgroups, CEneg, 199 
and CEpos, compared to reference group. For the survival curves in Figure 3 we used inverse 200 
probability weighting  to account for different proportions of RIF or RPL women and 201 
different age structure of mothers within the treatment groups.(23) For statistical analysis, we 202 
used STATA version 16.0, (STATA Corporation LLC, Texas, USA). We considered a p-203 
value < 0.05 as significant.  204 
 205 
Ethical approval 206 
The local ethical committee approved this study (BASEC & Kantonale Ethik Kommission 207 
Bern: 2017-01739), allowing for the use of encoded clinical data after patient information or 208 
the further use of biomaterials after informed consent retrieval. 209 
 210 
Results 211 
Population and diagnosis of chronic endometritis 212 
The flow-chart of the study population is presented in Figure 1. In total, 108 women fulfilled 213 
the inclusion criteria of whom 47 (43.5%) had RIF and 61 (56.5%) had RPL. From 2014-214 
2016 we performed only HSC in 41 (38.0 %) women (reference group); from 2016- 2018 we 215 
performed HSC with subsequent biopsy in 67 women. 24 (35.8%) women showed suspicion 216 
of CE at hysteroscopy with strawberry aspects, endometrial edema, irregular endometrium, 217 
and hyperemic areas with prominent leukoplakia (Figure 2). Among the women with biopsy, 218 
a total of 42 women were diagnosed positive for CE (CEpos) which refers to a prevalence of 219 
62.7%, and 25 (37.3%) women did not have any plasma cells according to histology and 220 
immunohistochemically CD138 staining (CEneg).  221 
Among the women with a biopsy, with HSC we could correctly identify 18 women as CE 222 
positive out of 42 (sensitivity of 42.8%) and 19 as CE negative out of 25 (specificity of 223 
76.0%) when comparing to immunohistochemically stained biopsy samples (P = 0.119). HE 224 
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staining alone was not sufficient to identify plasma cells as well, with only 11 women 225 
correctly diagnosed as positive for CE (sensitivity of 26.2%) and 21 as negative for CE 226 
(specificity of 84.0%) in comparison to immunohistochemistry (P = 0.333). False positive 227 
cells in HE staining were due mainly to pseudo-decidua of endometrial stromal cells, which 228 
could display a crescent-like cytoplasmic rim and represent a mimicker of plasma cells 229 
(Figure 2). The 41 patients diagnosed with CE (CEpos) took a first course of doxycycline and 230 
one women took ciprofloxacin. 231 
 232 
Patient characteristics 233 
Patient characteristics are displayed in Table 1. The reasons for infertility are different 234 
between RIF and RPL patients (P < 0.005) but not among the three studied groups. Nine 235 
patients with RPL suffered from endometriosis. 236 
 237 
Observation time 238 
The mean observation time until live birth or last follow-up date was the longest for the 239 
control group, with 1.86 years (SD 1.34). For CEneg the mean time was 0.88 years (SD 0.61), 240 
and for CEpos it was 0.75 years (SD 0.47).  241 
 242 
Fertility outcomes 243 
The chance for a clinical pregnancy and for a live birth was significantly higher for women 244 
with biopsy and subsequent management of endometrial pathology compared to the reference 245 
group (Table 2). The hazard ratio (HR), stratified for indication is 2.28 (CI 95% 1.23 – 4.24, 246 
P = 0.009) for a clinical pregnancy and 2.76 for a live birth (CI 95% 1.30 – 5.86, P = 0.008).  247 
Survival analysis shows a shorter time-to-pregnancy and to live birth for the biopsied women 248 
(Figure 3).  249 
In a subgroup analysis the chance for clinical pregnancy is highest for CEpos women (HR 250 
2.39, 95% CI 1.20-4.36, P = 0.010) and only somewhat higher for CEneg women (HR 2.04; 251 
95% CI 0.85-4.86, P = 0.110). This trend is also confirmed by subgroup analysis, independent 252 
if the women had RIF or RPL. Adjustment for maternal age and parity does not substantially 253 
affect the outcomes. All detailed results of the Cox regression are presented in Table 2. 254 
Detailed fertility outcome are presented in supplemental Table 1.  255 
  256 
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Discussion 257 
This is a historical cohort study on the effect of biopsy with subsequent management of 258 
endometrial pathology on time to live birth in women with RIF and RPL. Our results show 259 
that a diagnostic endometrial biopsy with subsequent diagnosis and treatment in case of CE is 260 
associated with reduced time-to-pregnancy and reduced time to live birth in both conditions, 261 
RIF and RPL. Women who had a biopsy and were treated for CE (CEpos) had the same 262 
chances compared to those without CE and a better chance compared to women with HSC 263 
only (reference group).  264 
This leads us to two hypotheses: first, diagnostic endometrial biopsy and CD138 staining with 265 
subsequent treatment of CE is important in the high-risk population of women with RIF and 266 
RPL; and second, even women not diagnosed with CE may achieve a better reproductive 267 
outcome in a shorter time after a diagnostic endometrial biopsy.  268 
Our study has two strengths: a differentiated diagnostics with HSC, endometrial biopsy, and 269 
immunohistochemically staining for CD138; an outcome that was not yet investigated in 270 
combination with CE, namely time-to-pregnancy and live birth. The sensitivity of our HSC 271 
investigation correlates well with a study published recently. (12) 272 
Our study also has several limitations. First it is an observational historical cohort and the 273 
sample size is limited. We analyzed patients with RIF and RPL as one group. Even though we 274 
did this on purpose, it might be questionable. We therefore focused on time to live birth as the 275 
main outcome and addressed this problem by a stratification of the Cox regression models for 276 
RIF and RPL. For the survival curves in Figure 3 we used inverse probability weighting to 277 
account for different proportions of RIF and RPL and different age structure of mothers.(23) 278 
Live birth as outcome is valid for both conditions and subgroup analysis confirmed that the 279 
procedure is mainly beneficial for women diagnosed and treated for CE (CEpos) independent 280 
if they had RIF and RPL. The inclusion of women with ongoing pregnancy might result in 281 
slightly overestimating the results presented for live births. However, we were generally 282 
interested in the long-term follow-up of women after the intervention independent of the 283 
course between intervention and the recorded outcome. Compared to many other studies 284 
looking at one subsequent embryo transfer or the next subsequent pregnancy, we did not 285 
restrict the observation time under the assumption that processes may use some time and 286 
influence of interventions might be beneficial later. 287 
Our results is based on the suggestion that hysteroscopy alone or HE staining is no longer 288 
considered sufficient to clearly diagnose CE or to identify plasma cells (13). 289 
Immunohistochemically staining of CD138 cells is considered to be best practice, but there 290 
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are various methods regarding quantification and what threshold should lead to the 291 
confirmation of a diagnosis of CE (10). We chose a more conservative approach of 292 
diagnosing with the threshold of one plasma cell per high power field in the hot spot, which 293 
may have led to an overestimation of CE prevalence.  294 
CE is often associated with the presence of bacterial pathogens. This leads to an unbalanced 295 
resident microbiota of the uterus and abnormal pattern of lymphocyte subset in the 296 
endometrium which may influence reproductive immunology (24). The immunological 297 
changes may be associated with poor endometrial receptivity (25). We assume that treatment 298 
of CE helps to reconstitute the uterine microenvironment and patterns of lymphocytes. This 299 
might strengthen the endometrial receptivity and improve reproductive outcome.  300 
A prospective study analyzing immunologic cells within the endometrium of 178 RIF and 155 301 
RPL women revealed a significantly higher prevalence of uterine Natural killer cells (NKs) 302 
(53.2 vs 45.2 & 42.9%, P < 0.001) in women with RIF compared to women with RPL. 303 
However, all sub-fertile populations had increased percentage of peripheral type NKs (P = 304 
0.001), and exhibited increased of CD69+ activation (P = 0.005), higher levels of B cells (P < 305 
0.001), an elevated ratio of CD4:CD8 (P < 0.001) and a higher proportion of Th1+ CD4s (P = 306 
0.001) (26). Furthermore, defective endometrial prostaglandin synthesis has been observed in 307 
women with RIF (27). Based on the presence of uterine NK cells and defective prostaglandin 308 
synthesis, different immunological responses on the implantation process seems to be 309 
additionally unfavourable in women with RIF compared to women with RPL.  310 
Our results show a difference in time-to-pregnancy and, more important, time to live birth 311 
between the biopsy group and the reference group. It is questionable if the biopsy also has an 312 
impact on women without CE (CEneg) as their reproductive outcome also seem so benefit 313 
from the procedure. A scratch induces an inflammatory response and may trigger 314 
immunological reconstitution. (28,29) It might be particularly relevant in a more vulnerable 315 
RIF and RPL population. A large randomized controlled trial has recently shown that 316 
endometrial scratching following IVF or ICSI does not increase the implantation rate in a 317 
subsequent transfer cycle, but its effect in women with RIF or RPL or the long-term effect 318 
were not addressed in this trial.(30) Endometrial scratch injury was shown to be beneficial in 319 
a meta-analysis in women who had two or more implantation failures, but not for women with 320 
one failed embryo transfer only. The greatest effect was associated with double luteal 321 
endometrial scratch injury with pipelle.(16) It is not well researched what reactions are caused 322 
by endometrial scratch injury and by endometrial diagnostic biopsy and to what extent they 323 
can be considered as comparable.(29)  324 
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Our results support the increasing evidence that in women with either RIF or RPL, CE needs 325 
to be diagnosed and treated. Our results particularly show a shorter time to live birth. 326 
However, prospective studies with larger number of participants are needed. 327 
 328 
Conclusion 329 
Diagnostic endometrial biopsy with subsequent antibiotic treatment in case of chronic 330 
endometritis shortens time to live birth and time-to-pregnancy, compared to women 331 
undergoing hysteroscopy only.  Randomized clinical trials are needed to establish standards 332 
for diagnosis and treatment of CE and to cure implantation failure in the future.  333 
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Table and Figure legends 438 
Table 1 Patient characteristics and fertility characteristics 439 
Patient characteristics of the biopsy group and the reference group 440 
AMH: Anti-Müllerian Hormone, BMI: Body Mass Index, CE: Chronic endometritis, cm: 441 
centimeter, HSC: Hysteroscopy, m: mean, na: not applicable, n: number, PCOS: Polycystic 442 
ovary syndrome, RIF: Repeated implantation failure, RPL: Recurrent pregnancy loss, SD: 443 
Standard deviation 444 
a linear regression, b Pearson’s chi-squared test 445 
446 
Table 2 Chances for clinical pregnancy and live birth (Cox models) 447 
CE: Chronic endometritis, CEneg: women diagnosed negative for chronic endometritis, 448 
CEpos: women diagnosed positive for chronic endometritis, 95% CI: 95% Confidence 449 
Interval, HR: Hazard ratio, n: no, y: yes, RIF: Repeated implantation failure, RPL: Recurrent 450 
pregnancy loss 451 
° Cox regression models adjusted for maternal age (continuous) and parity (nullipar vs par) 452 
Stratified Cox regression models all stratified for repeated implantation failure or recurrent 453 
pregnancy loss 454 
455 
Figure 1: Study population  456 
RPL: Recurrent pregnancy loss, RIF: Repeated implantation failure, TESE: Testicular sperm 457 
extraction, HSC: Hysteroscopy, CE: Chronic endometritis, CEneg: women diagnosed 458 
negative for chronic endometritis, CEpos: women diagnosed positive for chronic endometritis 459 
460 
Figure 2: Images of patient with and without CE in hysteroscopy, hemalaun-eosin 461 
staining and immunohistochemically CD138 staining 462 
Comparison of a patient with bland endometrium (A,C,E) versus chronic endometritis 463 
(B,D,F) in hysteroscopy (A,B), conventional histology (C,D) and immunohistochemistry for 464 
CD138 (E,F). Note the reddish inflamed mucosal surface in chronic endometritis (B) 465 
and the intermingled plasma cells in endometrial stroma in immunohistochemistry (F, central 466 
region). These differences in plasma cell densities can’t be distinguished in conventional 467 
histology (C,D) of the same patients. Of note, regular endometrial glands serve as a positive 468 
internal control as CD138 also known as syndecan-1 is positive in epithelial cells. 469 
HSC: Hysteroscopy, CE: Chronic endometritis; HE: Hemalaun-eosin staining 470 
471 
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Figure 3:  Time-to-pregnancy and time to live birth  472 
Kaplan-Meier failure estimates. Observation time: from hysteroscopy or biopsy date to 473 
clinical pregnancy or live birth (expected live birth); with applied inverse probability 474 
weighting to account for the proportion of women with repeated implantation failure and 475 
recurrent pregnancy loss respectively as well as the maternal age structure within each of the 476 
groups compared (according to Cole SR & Hernan MA). 477 
P-values for the two groups compared: 478 
a) P = 0.009  b)  P = 0.008  c)  P = 0.327    d)  P = 0.004 479 
  480 
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Supplemental Table 1: Patient characteristics and fertility characteristics 481 
Patient characteristics of the women diagnosed with chronic endometritis (CEpos group), the 482 
women without chronic endometritis (CEneg group), both from biopsy group, compared to 483 
women with hysteroscopy only (reference group). 484 
AMH: Anti-Müllerian Hormone, BMI: Body Mass Index, CE: Chronic endometritis, cm: 485 
centimeter, HSC: Hysteroscopy, m: mean, na: not applicable, n: number, PCOS: Polycystic 486 
ovary syndrome, RIF: Repeated implantation failure, RPL: Recurrent pregnancy loss, SD: 487 
Standard deviation 488 
a linear regression, b Pearson’s chi-squared test 489 
 490 
Supplemental Table 2: Fertility outcomes 491 
Fertility outcomes of the women diagnosed with chronic endometritis (CEpos group), the 492 
women without chronic endometritis (CEneg group) both from biopsy group, compared to 493 
women with hysteroscopy only (reference group). 494 
HSC: Hysteroscopy, CE: Chronic endometritis, Tx: Therapy, CP: Clinical pregnancy, n: number of 495 
events or persons, y: year, RIF: Recurrent implantation failure, RPL: Recurrent pregnancy loss, na: not 496 
applicable 497 
** Fisher’s exact test 498 
° Cox regression 499 
+ Cox regression stratified for repeated implantation failure and recurrent pregnancy loss 500 
123
Table 1 - Patient characteristics and fertility characteristics
Biopsy group vs
RIF vs RPL RIF vs RPL reference group RIF vs RPL
m/n SD/% m/n SD/% m/n SD/% P value m/n SD/% m/n SD/% m/n SD/% P value P value P value
n 28 42 39 58 67 62 19 46 22 54 41 38 108 61 vs 47
Mean age (years)a 37.8 3.1 36.9 5.2 37.3 4.4 0.422 37.6 4.0 35.3 3.5 36.4 3.8 0.061 0.294 0.094
Median age (years) 37.9 na 37.4 na 37.7 na na 37.8 na 35.2 na 37.0 na na na na
Mean weight (kg)a 65.6 11.1 66.4 10.3 66.1 10.5 0.777 64.3 10.1 63.5 9.8 63.9 9.8 0.806 0.301 0.883
Mean height (cm)a 166.6 4.8 166.1 7.6 166.3 6.6 0.782 166.5 5.6 165.2 6.6 165.8 6.1 0.529 0.731 0.561
Mean BMI (kg/m2)a 23.7 4.2 24.1 3.8 23.9 3.9 0.689 23.2 3.5 23.3 3.8 23.2 3.5 0.924 0.396 0.661
Current smoker (n)b 3 10.7 8 20.5 11 16.4 0.286 3 15.8 0.0 0 3 7.3 0.053 0.172 0.957
AMH (pmol/l)a 34.1 38.6 26.0 31.1 29.7 34.7 0.375 23.1 18.5 23.4 32.3 23.2 26.5 0.971 0.334 0.459
Time from intention to conceive until HSC (years)a 5.3 3.6 4.0 2.7 4.5 3.1 0.080 4.6 3.3 3.2 1.9 3.9 2.7 0.104 0.257 5.0 vs 3.7 (P =0.02)
Deliveries before treatment  (n)b 
0 23 82.1 23.0 59.0 46.0 68.6 14.0 73.7 11.0 50.0 25.0 0.6
1 5 17.9 13.0 33.3 18.0 26.7 5.0 26.3 10.0 45.5 15.0 36.6
2 0 0.0 3.0 7.7 3.0 4.5 0.0 0.0 1.0 4.5 1.0 2.4
No. of embryos transferred before treatment (RIF)a 11 7.4 na 10.3 3.5 na 0.645 na
Reason for infertility (n)b
male factor 10 35.7 7 3.7
tubal factor 2 7.1 0 0.0
endometriosis 3 10.7 4 21.0
idiopathic 12 42.9 6 31.6
anovulation/PCOS 1 3.6 2 10.5
0.522 0.027
na 0.492 nana






Table 2: Chances for clinical pregnancy and live birth (Cox models)
unadjusted stratified Cox models adjusted stratified Cox models° unadjusted stratified Cox models adjusted stratified Cox models°
HR 95% CI P  value HR 95% CI P  value HR 95% CI P  value HR 95% CI P  value
Reference group (baseline) 1.00 1.00 1.00 1.00
Biopsy group 2.28 1.23-4.24 0.009 2.62 1.39-4.49 0.003 2.76 1.30-5.86 0.008 2.88 1.35-6.16 0.006
Maternal age (continuous) 0.94 0.88-1.01 0.083 0.92 0.86-0.99 0.018 0.97 0.89-1.06 0.547 0.96 0.87-1.05 0.364
Duration of subfertility (continuous) 1.05 0.96-1.14 0.301 0.95 0.81-1.12 0.572
Parity (y/n) 0.84 0.47-1.51 0.570 0.84 0.47-1.52 0.568 0.98 0.47-2.05 0.958 0.86 0.40-1.85 0.697
Smoking (y/n) 1.05 0.44-2.51 0.904 1.04 0.40-2.74 0.924
Subgroup analyses (stratified for RIF/RPL)
Reference group (baseline) 1.00 1.00 1.00 1.00
Diagnosed positive for CE 2.39 1.20-4.36 0.010 2.86 1.46-5.63 0.002 3.53 1.48-8.40 0.004 3.91 1.62-9.41 0.002
Diagnosed negative for CE 2.04 0.85-4.86 0.110 2.11 0.88-5.08 0.095 1.95 0.70-5.42 0.203 1.92 0.69-5.35 0.213
Subgroup analyses (not stratified for RIF/RPL)
RIF and biopsy 2.18 0.73-6.50 0.162 2.12 0.71-6.35 0.179 2.95 0.91-9.62 0.073 2.9 0.89-9.46 0.077
RIF and CEpos 3.03 0.85-10.90 0.089 3.23 0.88-11.89 0.078 5.88 1.42 - 24.28 0.014 6.78 1.63-28.10 0.008
RIF and CEneg 1.73 0.49-6.04 0.390 1.61 0.46-5.67 0.454 2.04 0.52-8.02 0.309 1.88 0.48-7.42 0.367
RPL and biopsy 2.33 1.10-4.96 0.027 2.98 1.36-6.52 0.006 2.63 0.99-7.00 0.052 2.76 1.04-7.35 0.042
RPL and CEpos 2.28 1.06-4.92 0.036 3.06 1.37-6.85 0.006 2.74 0.97-7.70 0.056 3.34 1.13-9.83 0.029
RPL and CEneg 2.73 0.81-9.20 0.107 2.61 0.73-9.35 0.138 2.31 0.75-11.15 0.298 1.62 0.30-8.69 0.573




Women with diagnosis of RIF or RPL between January 2014 and December 
2018 (n=127)
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Figure 1: Study population






Supplemental table 1 - Patient characteristics & fertility characteristics
P value P value
not diagnosed with CE (CEneg) P value P value P value over three groups over all  
RIF RPL Total RPL vs RIF RIF RPL Total RPL vs RIF RIF RPL Total RPL vs RIF ref/CEneg/CEpos RIF vs RPL
m/n SD/% m/n SD/% m/n SD/% m/n SD/% m/n SD/% m/n SD/% m/n SD/% m/n SD/% m/n SD/%
n 15 60 10 40 25 23 13 31 29 69 42 39 19 46.3 22 53.7 41 38 108 61 vs 47
Mean age (years) a 38.3 2.5 34.5 6.4 36.8 4.7 0.046 37.2 3.7 37.7 4.5 37.6 4.2 0.709 37.6 4.0 35.3 3.5 36.4 3.8 0.061 0.431 0.094
Median age (years) 38.1 na 36.0 na 37.7 na na 36.3 na 38.7 na 38.1 na na 37.8 na 35.2 na 37.0 na na na na
Mean weight (kg) a 66.5 7.8 69.4 9.5 67.7 8.4 0.440 64.6 14.1 65.4 10.5 65.2 11.5 0.841 64.3 10.1 63.5 9.8 63.9 9.8 0.806 0.376 0.883
Mean height (cm) a 166.8 4.2 169.2 10.6 167.8 7.4 0.458 166.3 5.6 165.1 6.3 165.45 6.1 0.554 166.5 5.6 165.2 6.6 165.8 6.1 0.529 0.372 0.561
Mean BMI (kg/m2) a 24 3.3 24.3 2.7 24.1 3 0.847 23.4 5 24.04 4.1 23.8 4.4 0.651 23.2 3.5 23.3 3.8 23.2 3.5 0.924 0.676 0.661
Current smoker (n) b 2.0 13.3 4 40.0 6.0 24 0.126 1 7.7 4 13.7 5 11.9 0.572 3 15.8 0 0 3 7.3 0.053 0.142 0.957
AMH (pmol/l) a 27.1 30.9 29.9 28.3 28.12 29.3 0.834 41.6 45.6 24.7 32.5 30.63 37.9 0.197 23.1 18.5 23.4 32.3 23.2 26.5 0.971 0.603 0.459
Time from intention to conceive until HSC (years) a 6.1 4.5 3.34 1.3 5 3.8 0.078 4.5 2 4.2 3 4.29 2.7 0.735 4.61 3.3 3.23 1.9 3.9 2.7 0.104 0.351 5.0 vs 3.7 (p=0.02)
Deliveries before treatment (n) b
0 13 86.7 7 70.0 20 80 10 76.9 16 55.2 26 61.9 14 73.7 11 50 25 61
1 2 13.3 2 20.0 4 16 3 21.1 11 37.9 14 33.3 5 26.3 10 45.5 15 36.6
2 0 0 1 10.0 1 4 0 0 2 6.9 2 4.8 0 0 1 4.5 1 2.4
No. of embryos transferred before treatment (RIF) a 10.1 4.8 na 12.31 9.59 na 10.3 3.5 na 0.567 na
Reason for infertility (n) b 8
male factor 3 20 7 53.8 7 3.7
tubal factor 2 13.3 0 0 0 0
endometriosis 2 13.3 1 7.7 4 21
idiopathic 8 53.3 4 30.8 6 31.6
anovulation/PCOS 0 0 1 7.7 2 10.5
Biopsy group (biopsy)
diagnosed with CE (CEpos)
Reference group (ref)
0.392 0.337 0.456 0.027





Supplemental table 2: Fertility outcomes 
P  value P  value
P  value P  value P  value over ref over all
RIF RPL Total RIF vs RPL RIF RPL Total RIF vs RPL RIF RPL Total RIF vs RPL CEneg/CEpos RIF vs RPL
n (%) 15 (60%) 10 (40%) 25 (23%) 13 (31%) 29 (69%) 42 (39%) 19 (46.3%) 22 (53.7%) 41 (38%) 108
Women with a first ClinP after Tx 5 (33.3%) 4 (40%) 9 (36.0%) 1.00** 5 (38.5%) 21 (72.4%) 26 (61.9%) 0.047** 5 (26.3%) 14 (63.6%) 19 (46.3%) 0.028** 0.102 0.001
First ClinP ended in miscarriage 2 (40.0%) 2 (50.0%) 4 (44.4%) 1 (20%) 12 (57.1%) 13 (50.0%) 0 (0.0%) 6 (42.9%) 6 (31.6%)
First ClinP ended in live birth 3 (60.0%) 2 (50.0%) 5 (55.6%) 4 (80.0%) 9 (42.9%) 13 (50.0%) 5 (100%) 8 (57.1%) 13 (68.4%)
Women with a second ClinP after Tx 1 (6.7%) 1 (10%) 2 (8.0%) 1.00** 0 (0%) 5 (17.2%) 5 (11.9%) 0.302** 0 (0.0%) 4 (18.2%) 4 (9.8%) 0.111 ** 0.872 0.015
Second ClinP ended in miscarriage 0 (0.0%) 1 (100.0%) 1 (50.0%) 0 (0.0%) 3 (60.0%) 3 (60.0%) 0 (0.0%) 1 (25.0%) 1 (25.0%)
Second ClinP ended in live birth 1 (100.0%) 0 (0.0%) 1 (50.0%) 0. (0.0%) 2 (40.0%) 2 (40.0%) 0 (0.0%) 3 (75.0)% 3 (75.0%)
Total number of ClinP (first and second) 6 (40.0%) 6 (60.0%) 12 (80.0%) na 5 (38.5%) 26 (89.7%) 30 (71.4%) na 5 (26.3%) 18 (81.8%) 23 (56.1%) na na na
Total number of miscarriages after ClinP (n) 2 (13.3%) 3 (30.0%) 5 (20.0%) 1 (7.7%) 15 (51.7%) 16 (38.1%) 0 (3.2%) 7 (31.8%) 7 (17.1%) 0.339 0.011
Total number of live births (n) 4 (26.7%) 2 (20.0%) 6 (24.0%) 4 (30.8%) 11 (37.9%) 15 (35.7%) 5 (26.3%) 11 (50.0%) 16 (39.0%) 0.445 0.205
median time to ClinP  (years) na 0.48 na 0.237° 0.89 0.47 0.56 0.263° na 0.62 1.44 0.014° 0.023+ <0.001°
median time to live birth (years) na 1.14 na 0.472 1.14 1.24 1.21 0.223 na 2.08 2.27 0.182 0.013+ 0.197°
Women with an embryo transfer after Tx (RIF) 12 (80.0%) 9 (69.2%) 14 (73.7%) 0.804 na





















6.1. Main findings 
Small-for-gestational age 
This project investigated birthweight and birthweight percentiles after cIVF and NC-IVF. Birthweight 
percentile is a better outcome measure than birthweight alone, as it is adjusted for gestational age 
and sex of the infant. After cIVF, 11.8% of singletons were small-for-gestational-age compared to 
2.9% after NC-IVF in the Bern IVF Cohort. The odds were significantly increased when 
supraphysiological estradiol levels (>10’000pmol/l) in the maternal serum were detected at trigger 
day (unadjusted OR 4.58 95% CI 1.35 – 15.55; p=0.015). After adjustment for maternal height, age 
and body mass index it remained significant (aOR 3.83; 95% CI 1.06-18.82; p=0.041)1. These findings 
are in line with the work by Pereira et al. and are also supported by the findings from Sunkara et al. 
They both found higher risks associated with high estradiol level or a high amount of oocytes 
collected.2–4  
Breastfeeding after ART treatment 
It is reassuring that in Switzerland ART treatment does not affect the initiation or duration of 
breastfeeding in the first year after delivery. Mothers after IVF reach the same high breastfeeding 
prevalence (93.4 %) compared to mothers from the control group (94.8%).5 Additionally, hormonal 
stimulation is not associated with lower breastfeeding prevalence or earlier breastfeeding cessation 
as no differences between cIVF or NC-IVF were found. Factors associated with lower breastfeeding 
prevalence or earlier cessation in the whole study population were factors already familiar from the 
literature: maternal smoking during pregnancy, high BMI, low-birthweight, primiparity, preterm-birth 
and lower education. Mothers with IVF treatment smoked less and had a lower BMI, but had a 
slightly higher proportion of low-birthweight, preterm birth and were more often primiparous.  
Endometrial thickness in NC-IVF women 
The optimal endometrial thickness for achieving a pregnancy in a NC-IVF treatment is between 8-
11mm. The pregnancy rate in women with endometrial thickness ≤7mm was 7.4% and in women 
with >7mm it was 30.8%, but live birth rate did not differ. Quadratic regression analysis showed that 
thick endometrium is also associated with lower pregnancy success. Thin or very thick endometrium 




Time to pregnancy in women with RPL and RIF 
In a historical cohort of 108 women fulfilling the inclusion criteria, 47 were diagnosed with RIF and 61 
with RPL. From 2014 – 2016, 41 women had a hysteroscopic assessment only (reference group). Of 
67 women who had a biopsy from 2016-2018, 42 were diagnosed positive for chronic endometritis 
and 25 were negative in immunohistochemically staining of plasma cells (CD138). Women who had 
an endometrial diagnostic biopsy with subsequent diagnosis and treatment in case of chronic 
endometritis had a significantly higher chance for a clinical pregnancy (Hazard ratio (HR) = 2.28, CI 
95% 1.23 – 4.24, p=.009) and for a live birth (HR = 2.76, CI 95% 1.30 – 5.87, p=.008) compared to the 
reference group. In subgroup analysis it was found that women diagnosed positive for CE also had a 
high chance for clinical pregnancy (HR=2.39; 95% CI 1.20 – 4.36; p=.010) and live birth (HR=3.53; 95% 
CI 1.48 – 8.40; p=.004) compared to the women of the reference group. The indication of RIF or RPL 
did not substantially affect the outcome of the analysis. This finding demonstrates the importance of 
endometrial diagnostic biopsy and the subsequent treatment in case of a positive result for CE, in 
women suffering from both, RIF and RPL. However, it also shows that women without CE might 
benefit from an endometrial biopsy, which is similar to an endometrial scratch injury caused by the 
endometrial diagnostic biopsy. This was also found by Vitagliano et al.7 It has been shown that 
endometrial scratch injury influences immunological processes in the endometrium of the uterus.8 It 
would be important to confirm these findings through a randomized controlled trial.  
6.2. Broader interpretation of the findings 
Hormonal stimulation IVF 
Gonadotropin stimulation seems to be especially risky for women with a strong response to 
stimulation. However, it is difficult to predict a woman’s response to the gonadotropin stimulation. 
Generally, it can be said that women of younger ages, with a good ovarian reserve and a normal body 
weight, are at higher risk of generating a high response.9 High-responders are at higher risk of 
developing OHSS, which may interfere with early pregnancy and may potentially affect the intellect 
in the offspring.10 In Natural cycle IVF there is no risk for multiple pregnancies, as usually only one 
embryo is generated. Natural cycle IVF allows the research of the influence of the hormonal 
stimulation in singletons born after ART per se, as the only difference between cIVF and NC-IVF is the 
use of gonadotropins. In both treatments, other underlying factors remain similar. Parents of both 
treatments suffer from subfertility, and laboratory technologies and embryo culture are comparable. 
NC-IVF is therefore a suitable model to research the effects of the hormonal stimulation on the 
health of children.11,12 On the other hand, NC-IVF is not offered by many centres providing fertility 
treatment. This makes it difficult to achieve numbers high enough to get sufficient power for 
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statistical analysis. It would be necessary to collaborate with other centres, even at an international 
level, to set up cohorts large enough. However, even a reduction in the doses of hormones in 
minimal stimulation IVF is beneficial for the mother and the child, and should be considered by more 
treating centres.13,14  
Outcomes of ART research 
One of the most important outcomes in reproductive medicine has long been and remains the 
pregnancy rate. Clinical pregnancy is usually confirmed by the detection of an amniotic sac by 
ultrasound. It is not even agreed, if confirmation also involves the heartbeat of a viable embryo. This 
means that an amniotic sac absent a viable embryo would count as a successful outcome, were the 
endpoint is defined as such. For some years now, a shift towards live birth rate as a more suitable 
outcome has been in progress. The aim of the fertility treatment is a healthy newborn, and not a 
clinical pregnancy with unsure outcome.15 However, according to the DOHaD theory perinatal health 
matters, and may matter throughout an entire human life.16,17 This raises the question – is live birth 
the correct desired outcome? Should perinatal health, at least, if not long-term health, be assessed? 
Quite a lot of research exists on childhood health after ART. For adulthood, many of the cohorts are 
still too young. ART technologies develop so quickly that the health of adults researched today may 
not be relevant for children born after ART today. Therefore, perinatal health is often the most 
feasible proxy measure for long term health outcomes. Nevertheless, it remains important to 
establish cohorts, or to access informative data from existing cohorts and registries and to follow-up 
existing cohorts until adult life.18 
Unexplained infertility 
In fertility treatment, there are still a high proportion of couples with so-called unexplained infertility. 
It is possible that some problems leading to unexplained infertility have not yet been identified, and 
research is scarce. For many suspected causes of unexplained infertility, no randomized controlled 
trials have been conducted and no treatment guidelines exist.19,20 This is especially true for infertility 
due to endometriosis, and for women with RIF and RPL. It seems that immunological problems may 
play a role in some cases of unexplained infertility. Immunological aspects are also suspected to be 
associated with RIF,RPL and chronic endometritis.21 
Women’s health matters 
Many female health problems are not well researched. A report from Public Health England revealed 
that 31 % of women suffered from a reproductive or gynaecological problem within a 12 month 
period, but only a very small proportion of funding is allocated to this area.22,23 Underfunding may 
lead to many small observational single-centre analyses. But this will not help to find evidence on 
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pending questions. What is really lacking for many unresolved issues in female fertility are well-
conducted, randomized controlled trials with a sufficient power to detect possible differences among 
the groups compared. This becomes even more difficult with rare conditions, which would require 
collaborative efforts. RIF and RPL is a well-documented example of such a condition. Many published 
studies exist with women suffering from RIF and RPL but most of them are small and of a 
retrospective study design. Because diagnosis of CE is not standardised, comparability of the results 
is not possible.24 Recently, a first RCT on diagnosing CE though fluid hysteroscopy was published.25 On 
www.clinicaltrials.gov one RCT on antibiotic therapy in CE conducted in China is recorded.26 Not one 
single RCT on the treatment of CE has been published so far.  
Problems in current ART research 
The influence of ART on the health of children is a very complex subject, with many influencing 
factors, mediators and confounders. It remains difficult to identify the true origin of adverse 
outcomes in children born after ART. Several factors are involved when a couple seeks fertility 
treatment. Besides the ART technologies and the hormonal stimulation, other particularly important 
factors include underlying parental health, parental age and the particular causes of subfertility.27 As 
nowadays childbearing is often postponed for many reasons, the average maternal age is above 30 in 
most European countries, including Switzerland. Parents seeking fertility treatment are usually older; 
a high proportion is between 35-40 years. Pregnancy at age 35 – 40 is associated per se with higher 
risks of pregnancy complications and adverse perinatal outcomes.28,29 One of the pending questions 
is how to separate the parental influence from any epigenetic changes induced through ART by 
applying sensible research methodologies. In current ART research, this separation remains 
especially crucial. Much published research cannot answer these questions. The main problems are: 
I) Small single-centre cohort studies; II) The selection of an appropriate control group; III) The 
comparison of diverse reproductive technologies making the aggregation of results difficult for 
systematic reviews and meta-analyses; and IV) The frequent lack of details on the ART treatment in 
large population-based studies.30 The problem of selecting an appropriate group for comparison is 
discussed by Berntsen et al. Either spontaneously conceived children of subfertile couples or 
discordant siblings would be valuable controls.27 To identify spontaneously conceived children born 
to subfertile couples, pregnancies caused by IUI could be examined. In couples not using any medical 
support for conception, the time until conception is either not documented, or relies on self-
reported information provided by the couple. Discordant sibling couples are rare and difficult to 
identify. Only a few studies have used discordant siblings as controls.31–34 One study used sibling 
couples where one was born after a fresh embryo transfer and the other after FET to explore the 
cause for LGA.35 The differences in perinatal outcomes between pairs of siblings were lower 
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compared to existing research31,34, or not present.33 This supports the hypothesis that parental 
factors and subfertility are the primary influences on health outcomes in children.  
6.3. Strengths and limitations 
The strengths and limitations of each study are discussed in detail in each of the presented 
manuscripts.  
The Bern IVF Cohort is a unique cohort of IVF children, with data on the parents, the details of the 
treatments and pregnancies, as well as birth outcome. The proportion of parents consenting is high, 
and the children are followed-up on until today. This cohort is a great opportunity for future 
research, including research on long-term health outcomes. The possibility of connecting perinatal 
outcomes to detailed treatment information and detailed laboratory data is a strength of the 
projects. Bern is a specialist centre for natural cycle IVF. NC-IVF is offered to all women with regular 
menstrual cycles, and the decision on treatment is made together with the physician. This is the 
reason why nearly half of the live births came following an NC-IVF treatment. This allows the study of 
the influence of gonadotropins. Comparable cohorts are rare, even on an international level.  
Generally, all projects face the typical problems of research into ART, as discussed in the 
introduction. All are using data of one single centre, have a limited sample size and are 
retrospectively observational. Only one study included a control group for comparison. As patients 
treated by IVF or ICSI are highly selected already, it is difficult to find a good group for comparison. If, 
as in the manuscripts presented, data of a sample of the population is used, information on 
conception is often lacking. Children conceived with the support of ART methods are therefore 
present in the samples. The proportion of children born after ART in Switzerland is about 2-2.5%.36 
The contamination caused by this proportion can be considered to be low, and will not affect the 
medians of the groups for comparison.  
This thesis demonstrates the possibilities and difficulties of ART research very well. When the goal is 
to investigate children’s outcomes, it is not easy to find enough children born after the different 
treatment methods. This necessitates the collection of the data over several years, or collaboration 
with other ART centres. In multicentre studies, there are issues around the comparability of 
treatment schemes, as well as laboratory procedures, which might be different at each centre. It 
therefore increases the sample size by introducing more heterogeneity. As ART develops rapidly and 
the law changes, similar issues arise with collecting data over many years. For example, in 2017 the 
reproductive medicine act (RMA) was changed and allowed the extension of cultural duration until 
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day 5. Since then, pregnancy rates have increased in Switzerland.37 But it also introduced an 
additional confounder when comparing children created before or after the change.  
It is important to understand that ART is quite a special domain within medicine. Firstly, there are 
strict laws in place, clearly defining what is allowed and what is forbidden. Many ethical aspects are 
linked to ART. Society and politics may influence the scope of such a law. The RMA of Switzerland is, 
in comparison to other European countries, rather strict. It does not allow surrogate motherhood or 
egg donation. Furthermore, it does not allow the treatment of homosexual couples. However, it does 
allow sperm donation, which raises questions as to gender equity regarding accessing fertility 
treatment. 
Fertility treatment is not covered by the mandatory health insurance, which all persons have in 
Switzerland. Only diagnosis, and up to three IUI and/or the stimulation of ovulation by hormones up 
to one year, is reimbursed. All IVF or ICSI treatments have to be paid for by the couples themselves. 
This leads to a selection bias, as more couples who are able to afford treatment will go for fertility 
treatment. For less privileged couples, it may lead to a further delay of treatment onset, as money 
may have to be saved first.  
All these aspects may limit the transferability of the results of ART research to other countries.  
6.4. Implications for future research  
Access to data 
The Swiss Society for Reproductive Medicine (SGRM) collects data on fertility treatment within 
Switzerland via its national database on ART (FIVNAT-CH). FIVNAT-CH was founded in 1993 and 
remains active today. It reports key figures on a yearly basis to the Federal Statistical Office (FSO). 
The RMA requires the cantons to collect the data, and to monitor the quality of fertility treatment.  
In the FIVNAT-CH, data on fertility treatment on a national level is available for monitoring and 
quality control.38 It would be desirable to allow access to this data for research. This would require 
certain changes in the way the SGRM and the FIVNAT-CH are organised. First, the FIVNAT-CH would 
need ethical approval to collect the data for the purpose of research. Only recently, Swissethics 
introduced a basic ethical approval for registries collecting health-related personal data.39 Several 
medical associations have published guidelines on how to establish a medical registry.40 This would of 
course require the centres to adequately inform their patients, and to collect informed consent. 
Second, the SGRM would need to clearly regulate access to the data for the purposes of research. A 
process of requesting data, and of the validation of research projects by the steering board of SGRM 
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or FIVNAT-CH would need to be put in place. It would allow research with larger dataset on a 
national level.40 Standardized and high-quality data, including pregnancy and birth outcomes, should 
be collected systematically. Variable collection could be extended to allow the investigation of 
important research questions. Follow-up research on families, where informed consent is granted 
accordingly, would be possible. This would allow the contacting of families for future research on the 
long-term health consequences of ART. ART data collection must also adequately follow changes in 
treatment options. Today, with the possibility of freezing oocytes for social or medical reasons, or the 
vitrification of embryos, the fertility treatment of the same individual can last over decades.41,42 
Transparency 
Data collected within FIVNAT-CH is used to monitor the number of cycles conducted in fertility 
treatment and the number of children born following ART in Switzerland.38,43 It allows certain 
conclusions to be drawn about the characteristics of the couples in treatment, treatment success and 
the children born. However, it is not yet used to assess the quality and outcome of the centres in a 
standardized way. Instead, each centre is asked to provide its own key performance indicators. Even 
if they are defined, differences in assessing them may exist. Each centre also determines how 
transparently they report their figures. Calculating the key performance indicators should be done 
centrally and independently by using the numbers of FIVNAT-CH. FIVNAT-CH should include all 
variables necessary to be able to independently calculate the performance of the centres.  
Furthermore, FIVNAT-CH and the FSO only collect data on couples seeking treatment in Swiss fertility 
clinics. Compared to other European countries, RMA in Switzerland is still rather restrictive, and costs 
for fertility treatment are high. This leads to reproductive tourism, with Swiss couples seeking fertility 
treatment abroad. In Switzerland, it is impossible to estimate the number of couples seeking help 
abroad, or to know how many children are born in Switzerland after ART treatment abroad. FIVNAT-
CH, on the other hand, documents foreign couples seeking treatment within Switzerland. A European 
or international collaboration of national registries would be necessary to enable the extent of 
reproductive tourism to be estimated. It would also require standardized data collection on an 
international level to better aggregate and exchange data. ISMAARC and ESHRE are currently 
improving their data collection.44 This will possibly help in future to estimate the extent of fertility 
tourism by Swiss couples.18,41 
Health of children should be the focus 
Research on perinatal outcomes in children born after ART in Switzerland has so far been limited to 
qualitative aspects analysed within the FIVNAT-CH data.38,43 
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The Bern IVF Cohort is the first Swiss cohort to have been set up with the aim of also investigating 
the long-term health of children born after different ART treatments.  
Previously, research conducted by fertility specialists on the long-term health consequences in 
children born after ART in Switzerland did not exist. It was a bit of a surprise when cardiologists 
around Urs Scherrer communicated the higher cardiovascular health risks they discovered in children 
born after ART. It led to a media response throughout Switzerland, and even at international level. 
Many fertility specialists in Switzerland found themselves confronted with patients asking critical 
questions. This would be the moment for specialists engaged in fertility treatment to wake up and to 
create a supportive atmosphere to facilitate research. It is the moment to seek collaborations. It is 
our responsibility towards our patients to become more engaged in research, or at least to facilitate 
it with better data and improved access to it.45 
Future research projects 
As a first step, it would be important to investigate the perinatal health of children born after ART in 
comparison to that of children born to fertile couples within Switzerland. FIVNAT-CH and the Bern 
IVF Cohort could be a good basis on which to establish research focused on long-term follow-up in 
Switzerland.  
Long-term cardiovascular consequences should be investigated in collaboration with cardiologists. 
Children from the Bern IVF Cohort could be asked to participate in follow-up investigations.  
Linkage studies with data from FIVNAT-CH would allow the identification of risks of other diseases. 
Many registries exist in Switzerland, some on typical childhood diseases. A linkage with the registry 
for childhood cancer, for example, would be an option. 
A linkage with the Swiss NeoNet registry would allow the identification of children born at very low 
gestational age, to further research and follow up the risks of very preterm birth after ART.  
A randomized, blinded multicentre study should be set up on the diagnosis and treatment of women 
with RIF and RPL. It would be important to define clear inclusion criteria. As number of women with 
these conditions are not many, an international approach could be considered. Women diagnosed 
with CE would get a blinded course of antibiotics or placebo. One months later, a test for cure should 
be performed by endometrial biopsy. A crossover design could be considered to give the chance for 
treatment to each women participating in the trial. The women should then be followed up for at 
least one year.  
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6.5. Implications for future policy  
Society and fertility 
The trend towards the postponement of childbearing has been observed for decades across all 
European countries. Many explanations highlight changes in women’s position and opportunities 
within society. However, women’s actual reasons for the postponement of childbearing are not well 
researched nor understood. Especially in Switzerland, not much research exists on topics such as 
fertility awareness, parity progression, child wish or aimed family size. This leads to the fact that it is 
not well known how women could be motivated to move towards having children at younger ages. 
Which political measures would have to be taken to encourage younger couples to build a family? To 
sociologically and demographically research these questions might allow politics to improve 
circumstances for couples to start families earlier. The positive effect would be to lower the use of 
ART due to ageing. 
Access to fertility treatment 
Unequal access to fertility treatment may be increasing the risks for offspring. In Switzerland, only 
very basic fertility treatment is paid for by the mandatory health insurance. Neither IVF nor ICSI are 
covered, denying access to couples with lower financial resources. It also leads to couples delaying 
treatment during their more fertile years increasing risks for the mothers and the children. Access to 
fertility treatment should be equal for all genders and couples independent of their sexual 
orientation.46  
Towards safer ART in Switzerland 
Research, alongside ever-increasing experience and knowledge, leads to a reduction of some of the 
risks associated with birth following ART. For example, many countries have now moved towards a 
single embryo transfer policy. Low-dose stimulation schemes and variations, and the further 
development of cIVF have also reduced certain risks associated with gonadotropin stimulation as well 
as the number of embryos generated. Laboratory procedures have developed rapidly, and freeze-all 
strategies avoid the interference of hormonal stimulation with the onset of pregnancy. However, 
while clear answers are missing for some of the new technologies, the causes of any poorer perinatal 
outcomes often seem to be a combination of parental factors and ART itself. The one thing that is 
crystal clear is that multiple pregnancies bear the highest risk of adverse perinatal outcomes. Despite 
this clear evidence, the transfer of multiple embryos is still common in many countries, leading to 
twin and higher-order pregnancies. It would be advisable for Switzerland to employ a policy of single 




The following findings can be drawn from the different research projects described in this thesis: 
I) There is a need to further investigate the effects of gonadotropin stimulation; and NC-IVF
provides an opportunity to do this;
II) Child health and long-term outcomes should be the focus of reproductive medicine,
rather than the current focuses of pregnancy rates and live birth rates;
III) Many reasons for infertility and women’s health are still unresolved and require further,
more focused and well-designed research.
The main conclusion is that fertility treatment matters and better research on fertility treatment 
should be encouraged, especially in Switzerland. Numbers are often too low in any one centre so 
collaboration would be key to expanding and improving research.  
It remains difficult to disentangle all the influencing factors on child health. Gaining more knowledge 
on these aspects is crucial. Especially in a country, where maternal age at child birth, infertility and 
the use of ART will increase further, it is of tremendous importance to further improve the safety of 
ART treatment and to follow-up their future children.  
Personal conclusion 
This thesis was an excellent chance for me to increase my experience in research. It gave me insight 
in a topic, ART, where I had not previously had any knowledge. It also allowed me to combine my 
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